Itamar Medical (ITMR) 20-F 10 Apr 19 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document And Entity Information [Abstract]
Entity Registrant Name	Itamar Medical Ltd.
Entity Central Index Key	0001613170
Trading Symbol	itmr
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding	287,615,892
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Voluntary Filers	No

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 6,471	$ 7,643
Investments in marketable securities		3,173
Trade receivables	6,549	5,362
Other receivables	1,018	685
Inventories	2,235	2,260
Total current assets	16,273	19,123
Non-current assets
Long-term restricted deposits and prepaid expenses	365	382
Long-term trade receivables	243	473
Property and equipment	1,213	1,022
Intangible assets	298	277
Total non-current assets	2,119	2,154
Total assets	18,392	21,277
Current liabilities
Trade payables	1,517	1,262
Short-term employee benefits	222	223
Short-term bank loan	5,000
Current maturities of convertible notes		10,696
Provisions	215	183
Accrued expenses	1,034	1,405
Other accounts payable	2,063	1,998
Total current liabilities	10,051	15,767
Non-current liabilities
Derivative instruments	442	2,875
Long-term employee benefits	159	310
Other long-term liabilities	1,052	948
Total non-current liabilities	1,653	4,133
Total liabilities	11,704	19,900
Commitments
Equity
Ordinary share capital	748	683
Additional paid-in capital	111,486	105,585
Capital reserve from marketable securities available-for-sale		113
Accumulated deficit	(105,546)	(105,004)
Total equity	6,688	1,377
Total liabilities and equity	$ 18,392	$ 21,277

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Profit or loss [abstract]
Revenues	$ 24,189	$ 20,701	$ 18,440
Cost of revenues	5,726	5,002	4,979
Gross profit	18,463	15,699	13,461
Operating expenses:
Selling and marketing expenses	12,699	12,140	14,035
Research and development expenses	3,638	4,129	3,225
General and administrative expenses	5,247	5,278	6,213
Total operating expenses	21,584	21,547	23,473
Operating loss	(3,121)	(5,848)	(10,012)
Financial income from cash and investments	244	1,591	716
Financial expenses from notes, loans and other	(1,161)	(4,884)	(4,760)
Gain (loss) from derivatives instruments, net	2,433	3,925	(216)
Financial income (expenses), net	1,516	632	(4,260)
Loss before taxes on income	(1,605)	(5,216)	(14,272)
Taxes on income	(124)	(85)	(131)
Net loss	$ (1,729)	$ (5,301)	$ (14,403)
Loss per share (in U.S. dollars):
Basic (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.05)
Diluted (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.05)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of comprehensive income [abstract]
Net loss	$ (1,729)	$ (5,301)	$ (14,403)
Other comprehensive income (loss) items that will not be carried to the statements of operations
Actuarial gains (losses) of defined benefit plan, net of tax	166	(112)	(107)
Total other comprehensive income (loss) for the year that will not be carried to the statements of operations, net of tax	166	(112)	(107)
Other comprehensive income (loss) items that after preliminary recognition in comprehensive income (loss), were or will be carried to the statements of operations
Net change in fair value of marketable securities available-for-sale, net of tax		158	9
Net change in fair value of marketable securities through other comprehensive income (loss), net of tax that was transferred to the statements of operations	(113)
Total other comprehensive income (loss) items that after preliminary recognition in comprehensive income, were or will be carried to the statements of operations, net of tax	(113)	158	9
Other total comprehensive income (loss)	53	46	(98)
Total comprehensive loss	$ (1,676)	$ (5,255)	$ (14,501)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Ordinary share capital	Additional paid-in capital	Capital reserve from marketable securities available-for-sale	Accumulated deficit	Total
Beginning Balance at Dec. 31, 2015	$ 670	$ 104,486	$ (54)	$ (88,151)	$ 16,951
Total comprehensive loss:
Net loss				(14,403)	(14,403)
Other comprehensive income (loss), net of tax			9	(107)	(98)
Total comprehensive loss			9	(14,510)	(14,501)
Transactions carried directly to equity:
Issuance of shares due to the exercise of options	1	16			17
Issuance of shares and warrants, net of issuance costs	8	990			998
Share-based payment				1,776	1,776
Ending Balance at Dec. 31, 2016	679	105,492	(45)	(100,885)	5,241
Total comprehensive loss:
Net loss				(5,301)	(5,301)
Other comprehensive income (loss), net of tax			158	(112)	46
Total comprehensive loss			158	(5,413)	(5,255)
Transactions carried directly to equity:
Issuance of shares due to the exercise of options	4	93			97
Share-based payment				1,294	1,294
Ending Balance at Dec. 31, 2017	683	105,585	113	(105,004)	1,377
Total comprehensive loss:
Net loss				(1,729)	(1,729)
Other comprehensive income (loss), net of tax			(113)	166	53
Total comprehensive loss			$ (113)	(1,563)	(1,676)
Transactions carried directly to equity:
Issuance of shares due to the exercise of options	3	77			80
Issuance of shares, net of issuance costs	62	5,739			5,801
Share-based payment				1,021	1,021
Capital reserve from transactions with shareholders		85			85
Ending Balance at Dec. 31, 2018	$ 748	$ 111,486		$ (105,546)	$ 6,688

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (1,729)	$ (5,301)	$ (14,403)
Adjustments for:
Depreciation and amortization	481	509	434
Share-based payment	1,021	1,294	1,776
Capital gain from sale of property and equipment		(8)
Change in provision for doubtful and bad debt	104	147	849
Net financial cost	914	3,133	4,110
Loss (gain) from reevaluation of derivatives	(2,433)	(3,925)	216
Increase in trade receivables	(1,061)	(833)	(1,548)
Decrease (increase) in other accounts receivable	(330)	169	(157)
Increase in inventories	(340)	(711)	(430)
Increase (decrease) in trade payables	237	(66)	289
Increase in other accounts payable and accrued expenses	61	669	188
Increase (decrease) in employee benefits	14	67	(111)
Increase (decrease) in provisions	32	16	(71)
Income tax expenses	124	85	131
Taxes paid during the year	(176)	(83)	(228)
Net interest paid during the year	(802)	(1,344)	(1,675)
Net cash used in operating activities	(3,883)	(6,182)	(10,630)
Cash flows from investing activities:
Sale of marketable securities	3,109
Purchase of property and equipment, intangible assets and capitalization of development expenditure	(310)	(296)	(455)
Investment in restricted long-term deposits		(22)	(113)
Net cash provided by (used in) investing activities	2,799	(318)	(568)
Cash flows from financing activities:
Proceeds from issuance of shares and warrants, net of issuance costs	5,209		998
Short-term bank credit	5,000
Repayment of convertible notes	(9,939)	(10,421)
Issuance of warrants			85
Repayment of shareholders' loans	(435)
Issuance of shares due to the exercise of stock options	80	97	17
Net cash provided by (used in) financing activities	(85)	(10,324)	1,100
Decrease in cash and cash equivalents	(1,169)	(16,824)	(10,098)
Cash and cash equivalents at beginning of year	7,643	23,358	33,019
Effect of exchange rate fluctuations on balances of cash and cash equivalents	(3)	1,109	437
Cash and cash equivalents at end of year	6,471	$ 7,643	$ 23,358
Non-cash financing activity - conversion of notes to a loan from related parties and to shares	$ 1,076

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2018
General Information [Abstract]
GENERAL	NOTE 1 – GENERAL a. Reporting entity Itamar Medical Ltd. (the “Company”) is a company incorporated in Israel, with registered office at 9 Halamish Street, North Industrial Zone, Caesarea, Israel. The consolidated financial statements of the Company as of December 31, 2018 and 2017 and for each of the three years in the period ended December 31, 2018 comprise the Company and its subsidiaries (together referred to as the “Group”). The Company is engaged in research, development, sales and marketing of non-invasive medical devices for the diagnosis of respiratory sleep disorders with a focus on the cardiology market. The Company offers a Total Sleep Solution™ to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare costs. Its flagship Peripheral Arterial Tone biological signal (“PAT”) -based product, the WatchPAT™ device, is a home-use diagnostic device for sleep breathing disorders. It also offers the Endo PAT™ system, an FDA-approved device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases. The ordinary shares of the Company are listed on the Tel Aviv Stock Exchange Ltd. (“TASE”). On February 27, 2019, the Company’s American Depositary Shares (“ADSs”), each of which represents 30 ordinary shares of the Company, represented by American Depositary Receipts (“ADRs”), were registered for trade on the Nasdaq Capital Market. b. The Company’s financial position As described in Note 22a, during February and March 2019, the Company raised total consideration of $14.7 million in a private placement. In addition, as describe in Note 8a, on March 12, 2019, the Company increased its credit facility with a bank from up to $10 million to up to $15 million. The Company’s management and Board of Directors are in the opinion that, based on the positive trend of its operating results, the bank credit facility, the private placement and the Company’s ability to adjust its budget to business developments, the Company has enough financial resources in order to continue its business activities in the twelve-month period from the date of approval of these financial statements. In addition, management continuously assesses its actual results and monitors its financial covenants and is able to respond by reducing and monitoring its operating expenses in case it does not meet its targets.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES The accounting policies set out below have been consistently applied for all years presented in these consolidated financial statements, except for the new accounting standards and amendments to accounting standards, that the Group adopted commencing January 1, 2018, as described below: a. International financial reporting standards These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). These consolidated financial statements were approved by the Company’s Board of Directors on April 10, 2019. b. Reporting and functional currency These consolidated financial statements are presented in U.S. dollars (“dollar” or “$”), which is the Company’s functional currency representing the principal economic environment in which the Company operates, and have been rounded to the nearest thousand unless otherwise indicated. c. Basis of measurement These consolidated financial statements have been prepared on the historical cost basis, except for certain investments and derivatives and other financial instruments measured at fair value through profit or loss, provisions, and assets and liabilities with respect to employee benefits. d. Principles of consolidation Subsidiaries are entities controlled by the Company. The financial statements of the subsidiaries, which are wholly-owned, are included in the consolidated financial statements of the Company from the date of their incorporation. Intercompany balances and transactions between Group companies are eliminated in consolidation. e. Use of estimates and critical assumptions The preparation of financial statements in accordance with IFRS requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements as well as affect the reported amounts of revenues and expenses during the period. These estimates and assumptions are reviewed on an ongoing basis using available information. Actual results could differ from these estimates and assumptions. The items subject to significant estimates and assumptions by management include share-based compensation, the measurement of financial instruments at fair value, the fair value of the embedded warrant component of convertible notes, and the fair value of warrants where there is no active market. f. Foreign currency transactions and balances Transactions in foreign currency are translated to the respective functional currency of the Group entities at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between the amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency, translated at the exchange rate at the end of the year. Non-monetary assets and liabilities denominated in foreign currency that are measured in terms of historical cost, are translated using the exchange rate at the date of the transaction. Foreign currency differences arising from translation into the functional currency are recognized in the statements of operations. g. Changes in accounting policies - initial application of new standards and interpretations (1) IFRS 9 (2014), Financial Instruments As from January 1, 2018, the Group adopted IFRS 9, which replaces IAS 39, Financial Instruments: Recognition and Measurement IFRS 9 sets forth the guidance relating to the classification and measurement of financial assets and liabilities, the accounting for expected credit losses of financial assets and commitments to extend credits, as well as the requirements for hedge accounting. As described in section i below, the adoption of IFRS 9 did not have a material effect on the Company’s financial statements. (2) IFRS 15, Revenues from Contracts with Customers As from January 1, 2018, the Group adopted IFRS 15, which provides new guidance on revenue recognition. The Group elected to adopt IFRS 15, using the cumulative impact approach, with an adjustment to the balance of accumulated deficit as of January 1, 2018 and without restating the comparative figures. IFRS 15 introduces a new five step model for recognizing revenue from contracts with customers: (a) Identifying the contract with the customer. (b) Identifying distinct performance obligations in the contract. (c) Determining the transaction price. (d) Allocating the transaction price to distinct performance obligations. (e) Recognizing revenue when the performance obligations are satisfied. As to the revenue recognition policy applied by the Group as from January 1, 2018 under IFRS 15, see section q below. As part of the initial adoption of IFRS 15, the Group elected to implement the following exemptions: (a) Application of the cumulative impact approach only for contracts that have not been concluded at the date of transition; and (b) Examining the aggregate impact of changes in the contract that occurred before the date of initial application, instead of an examination of each change separately. For the year ended December 31, 2018, there was no impact to revenue and to cost of revenue as result of the adoption of IFRS 15. As of January 1, 2018 and December 31, 2018, the Group had an immaterial effect on its financial statements as a result of reclassifying contract liabilities, which were previously deducted from accounts receivables, as current liabilities in respect of contract assets that the rights in their respect are unconditional, together with a corresponding increase to deferred revenue in accordance with the guidance of IFRS 15. h. Cash and Cash Equivalents Cash and cash equivalents are comprised of available amounts of cash and cash equivalents, mainly represented by highly-liquid short-term investments (with original maturities of three months or less), which are readily convertible into known amounts of cash, and which are not subject to significant risks of changes in their values. i. Financial instruments: The accounting policy applied as from January 1, 2018 As from January 1, 2018, the Group applies the following accounting policies under IFRS 9, see also section g(1) above as to the effect of initial adoption. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition, based on the business model objectives and nature of the investment: amortized cost; fair value through other comprehensive income (loss) – investment in equity instruments; or fair value through profit and loss. Debt instrument is classified to amortized cost category if it meets both of the following conditions: - It is held within a business model whose objective is to hold assets so as to collect contractual cash flows; and - The contractual terms of the financial asset give rise to cash flows representing solely payments of principal and interest (“SPPI”) on the principal amount outstanding on specified dates. A debt instrument can also be classified to fair value through other comprehensive income category if its business model objective is achieved by both collecting contractual cash flows and selling financial assets, and it meets the SPPI criteria as above. In certain cases, a debt instrument can be designated at initial acquisition to fair value through profit or loss. As applicable to the Group, the Group’s debt instruments that are classified to amortized cost category include: deposits, trade and other accounts receivable (including long-term trade receivables). These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss. The Group’s debt instruments that were classified at fair value through other comprehensive income include debt marketable securities. These securities were realized in the beginning of 2018. The Group classifies its financial assets to fair value through profit and loss category, when: - It is a debt instrument that does not meet the above criteria; - It is an investment at fair value through other comprehensive income (loss) in equity securities; or - It is part of a portfolio of financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis. These assets are subsequently measured at fair value. As of December 31, 2018, the Group did not have such assets. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. Impairment of financial assets IFRS 9 replaces the impairment model of IAS 39 (“incurred loss” model), with an ‘expected credit loss’ (“ECL”) model. The model applies to financial assets measured at amortized cost, investments in debt instruments measured at fair value through other comprehensive income, contract assets (as defined in IFRS 15) and lease receivables, but not to investments in equity instruments. Under the new model, the Group assesses the expected credit losses in advance as follows: - for debt instruments that have low credit risk or for which no significant deterioration has occurred in their credit quality since initial recognition – the impairment loss will be assessed based on the expected credit loss in the period during the 12 months following the reporting date; and - for debt instruments for which a significant deterioration has occurred in their credit quality since initial recognition and their credit risk is not low, the impairment loss will be assessed based on the remaining life of the instrument. The Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables and contract assets. Non-derivative financial liabilities Non-derivative financial liabilities include loans and borrowings from banks and others, convertible notes, and trade and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Liabilities, which are convertible into shares, denominated in a currency different than the functional currency of the Company or linked to the Israeli Consumer Price Index (the “Israeli CPI”), constitute a hybrid instrument presented in full as a financial liability. For measurement, the instrument is separated into two components: (i) a liability component with no conversion feature, which is classified to amortized cost category, and (ii) a conversion option, which constitutes an embedded derivative accounted for as a derivative financial instrument at fair value and is measured through the statements of operations as part of “Financial income (expenses), net”. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) and the liability component of the hybrid instrument above are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled. Substantial modification in terms of debt instruments An exchange of debt instruments having substantially different terms, is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Furthermore, a substantial modification of the terms of an existing financial liability, or an exchange of debt instruments having substantially different terms between an existing borrower and lender, are accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability at fair value. In such cases the entire difference between the amortized cost of the original financial liability and the fair value of the new financial liability is recognized in profit or loss as financing income or expense. The terms are substantially different if the discounted present value of the cash flows according to the new terms, including any commissions paid, less any commissions received and discounted using the original effective interest rate, is different by at least ten percent (10%) from the discounted present value of the remaining cash flows of the original financial liability. Upon the swap of debt instruments with equity instruments, equity instruments issued at the extinguishment and de-recognition of all or part of a liability, are a part of “consideration paid” for purposes of calculating the gain or loss from de-recognition of the financial liability. The equity instruments are initially recognized at fair value, unless fair value cannot be reliably measured – in which case the issued instruments are measured at the fair value of the derecognized liability. Any difference between the amortized cost of the financial liability and the initial measurement amount of the equity instruments is recognized in profit or loss under financial income or expenses. Non-substantial modification in terms of debt instruments In a non-substantial modification in terms (or exchange) of debt instruments, the new cash flows are discounted using the original effective interest rate, and the difference between the present value of the new financial liability and the present value of the original financial liability is recognized in profit or loss. Offset of financial instruments Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Issuance of bundle of securities The consideration received from the issuance of a bundle of securities is attributed initially to financial liabilities measured each period at fair value, and then to financial liabilities measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the grant of the consideration from the issuance of the bundle, as described above. Derivative financial instruments The Group recognizes all derivative instruments as assets or liabilities in the statements of financial position at their estimated fair values, and the changes in such fair values are recognized in the statements of operations within “Financial income (expenses), net” for the period in which they occur. During the reported years, the Group did not have derivatives designated as hedges. The Group reviews its contracts to identify the existence of embedded derivatives. Identified embedded derivatives in hybrid contracts where the host is not an asset, are analyzed to determine if they need to be separated from the host contract and recognized in the statements of financial position as assets or liabilities, applying the same valuation rules used for other derivative instruments. Fair value measurements Under IFRS, fair value represents an “Exit Value”, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, considering the counterparty’s credit risk in the valuation. The concept of Exit Value is premised on the existence of a market and market participants for the specific asset or liability. When there is no market and/or market participants willing to make a market, IFRS establishes a fair value hierarchy that gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: · Level 1— Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group has the ability to access at the measurement date. A quote price in an active market provides the most reliable evidence of fair value and is used without adjustment to measure fair value whenever available. · Level 2— Inputs, other than quoted prices in active markets, that are observable for the asset or liability, either directly or indirectly, and are used mainly to determine the fair value of securities, investments or loans that are not actively traded. · Level 3— Unobservable inputs for the asset or liability are used when little or no market data is available. The Group used unobservable inputs to determine fair values, to the extent there are no Level 1 or Level 2 inputs, in valuation models such as Black-Scholes, binomial, discounted cash flows or multiples, including risk assumptions consistent with what market participants would use to arrive at fair value. The accounting policy applied in periods prior to January 1, 2018 Trade accounts receivable and other accounts receivable Trade accounts receivable and other accounts receivable are classified as loans and receivables and are recorded at their amortized cost representing the net present value of the consideration receivable or payable as of the transaction date. Due to their short-term nature, the Group initially recognizes these receivables at the original invoiced amount. Allowances for doubtful accounts were recognized based on incurred loss estimates against general and administrative expenses. Long-term trade receivables and other investments Long-term trade receivables are initially recognized at their amortized cost. Subsequent changes in net present value are recognized in the statements of operations as part of “Financial income (expenses), net”. Investments in financial instruments held for trading as well as those investments available-for-sale, are recognized at their estimated fair value, in the first case through the statements of operations as part of “Financial income (expenses), net” and in the second case, changes in valuations are recognized as part of “Other comprehensive income (loss)” for the year within “Capital reserve” until their time of disposition, when all valuation effects accrued in equity are reclassified to “Financial income (expenses), net” in the statements of operations. These investments are tested for impairment upon the occurrence of a significant adverse change or at least once a year during the last quarter. Debt and other financial obligations Bank loans and notes payable, are recognized at their amortized cost. Interest accrued on financial instruments is recognized within “Other accounts payable and accrued expenses” against financial expenses. Direct costs incurred in debt issuances or borrowings, adjust the carrying amount of the related debt and are amortized as interest expense as part of the effective interest rate of each instrument over its maturity. These costs include commissions and professional fees. In the statements of cash flows, interest received and interest paid on bank loans and notes payable are presented in cash flows from operating activities. Liabilities, which are convertible into shares, denominated in a currency different than the functional currency of the Company or linked to the Israeli CPI, constitute a hybrid instrument presented in full as a financial liability. For measurement, the instrument is separated into two components: (i) a liability component with no conversion feature, which is measured at amortized cost according to the effective interest method, and (ii) a conversion option, which constitutes an embedded derivative accounted for as a derivative financial instrument at fair value and is measured through the statements of operations as part of “Financial income (expenses), net”. Issuance of bundle of securities The consideration received from the issuance of a bundle of securities is attributed initially to financial liabilities measured each period at fair value, and then to financial liabilities measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the grant of the consideration from the issuance of the bundle, as described above. Derivative financial instruments The Group recognizes all derivative instruments as assets or liabilities in the statements of financial position at their estimated fair values, and the changes in such fair values are recognized in the statements of operations within “Financial income (expenses), net” for the period in which they occur. During the reported years, the Group did not have derivatives designated as hedges. The Group reviews its contracts to identify the existence of embedded derivatives. Identified embedded derivatives are analyzed to determine if they need to be separated from the host contract and recognized in the statements of financial position as assets or liabilities, applying the same valuation rules used for other derivative instruments. j. Inventories Inventories are valued using the lower of cost and net realizable value. The cost of inventories is based on the “moving-average” method, including expenditures incurred in acquiring the inventories and the costs incurred in bringing it to its existing location and condition. The Group analyzes its inventory balances to determine if, as a result of internal events, such as physical damage, or external events, such as technological changes or market conditions, certain portions of such balances have become obsolete or impaired. When an impairment situation arises, the inventory balance is adjusted to its net realizable value, whereas, if an obsolescence situation occurs, the inventory obsolescence reserve is increased. In both cases, these adjustments are recognized against the results of the period. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs to complete and sell the inventories. k. Property and equipment Property and equipment are recognized at their acquisition or construction cost, as applicable, less accumulated depreciation and accumulated impairment losses. Depreciation of property and equipment is recognized as part of operating expenses, and is calculated using the straight-line method over the estimated useful lives of the assets. As of December 31, 2018, the average useful lives by category of property and equipment were as follows: % Office furniture and equipment 10 Equipment and devices for leasing and for internal use 15 Computers 33 Leasehold improvements are amortized over the shorter of the lease term and their useful lives. Depreciation methods and useful lives are reviewed at the end of each reporting year and adjusted if appropriate. l. Intangible assets The Group capitalizes intangible assets acquired, as well as costs incurred in the development of certain intangible assets for internal use, when future economic benefits associated are identified and there is evidence of control over such benefits. Intangible assets are recognized at their acquisition or development cost, as applicable. All of the Group’s intangible assets are definite life intangible assets, and are amortized on straight-line basis over the useful life of the asset, which on average is approximately three years. Expenditure on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of operations when incurred. Development activities are related to a plan to produce new products or processes, or to significantly improve existing products or processes. Development expenditure is capitalized only if: (i) the expenditure can be measured reliably; (ii) the product or process is technically and commercially feasible; and (iii) future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use. Other development expenditure is recognized in the statements of operations as incurred. In subsequent periods, capitalized development expenditure is measured at cost less accumulated amortization and any accumulated impairment losses. Amortization methods and useful lives are reviewed at the end of each reporting year and adjusted if appropriate. m. Impairment of property and equipment, intangible assets of definite life and other investments These assets are tested for impairment upon the occurrence of factors such as the occurrence of a significant adverse event, changes in the Group’s operating environment or in technology, as well as expectations of lower operating results, in order to determine whether their carrying amounts may not be recovered. An impairment loss is recorded in the statements of operations for the period within “Other expenses, net”, for the excess of the asset’s carrying amount over its recoverable amount, corresponding to the higher of the fair value less costs to sell the asset, and the asset’s value in use, the latter represented by the net present value of estimated cash flows related to the use and eventual disposal of the asset. No impairment loss was recorded during the reported years. n. Provisions The Group recognizes provisions when it has a legal or constructive obligation resulting from past events, whose resolution would imply cash outflows or the delivery of other resources owned by the Group. Obligations or losses related to contingencies are recognized as liabilities in the statements of financial position only when present obligations exist resulting from past events and it is probable to result in an outflow of resources and the amount can be measured reliably. Otherwise, a qualitative disclosure is included in the notes to the financial statements. The provisions are determined by discounting the future cash flows at a pre-tax interest rate, reflecting the current market estimates of the time value of the money and the specific risks of the liability without weighting the Group’s credit risk. The carrying value of the provision is then adjusted in every period so as to reflect the passage of time and the adjustment amount is credited to financial expenses. o. Post-employment benefits The costs of defined contribution plans are recognized in the operating results as they are incurred. Liabilities arising from such plans are settled through cash transfers to the employees’ retirement accounts with insurance companies or with funds managed by others, without generating future obligations. The majority of the Israeli employees are under defined contribution plans. The rest of the Israeli employees are under defined benefit plans. The costs associated with defined benefit plans are recognized as services are rendered, based on actuarial estimations of the benefits’ present value with the advice of external actuaries. p. Share-based payment transactions The grant-date fair value of share-based payment awards granted to employees and directors is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees and directors become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest. For share-based payment awards with non-vesting conditions or with market performance vesting conditions, the grant date fair value of the share-based payment awards is measured to reflect such conditions, and therefore the Group recognizes an expense in respect of the awards whether or not the conditions have been met. The fair value at the time of grant of share-based payment awards to consultants and service providers are recognized over the consultants’ and the service providers’ period of service against an increase in equity. The fair value of the services is calculated on the basis of the fair value of the awards and not on the basis of the fair value of the services, since it is not possible to reliably estimate the fair value of the services rendered. The Group elected to record the increase in equity against salary expense directly to accumulated deficit. q. Revenue recognition The accounting policy applied as from January 1, 2018 As from January 1, 2018, the Group applies the following accounting policies under IFRS 15. See also section g(2) above as to the effect of initial adoption. The Group recognizes revenues when the customer obtains control over the products or services that have been secured, net of provision for returns and discounts. The revenue is measured according to the amount of consideration that the Group expects to be entitled to in return for the transfer of products or services promised to the customer, other than amounts collected in favor of third parties. The Group recognizes estimated sales discounts as a reduction of sales in the same period revenue is recognized. The Group adjusts reserves to reflect differences between estimated and actual. The Group estimates its sales returns reserve based on historical return rates and analysis of specific accounts. When the Group sells its products through distributors, revenue is being recognized upon delivery of the product to the distributor, as the distributors

TRADE AND OTHER RECEIVABLES

TRADE AND OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2018
Trade and other receivables [abstract]
TRADE AND OTHER RECEIVABLES	NOTE 3 - TRADE AND OTHER RECEIVABLES December 31, 2018 2017 U.S. dollars in thousands Trade receivables: Open accounts $ 7,040 $ 6,048 Checks receivable 22 327 7,062 6,375 Less - allowance for doubtful accounts 270 540 6,792 5,835 Is presented in the statements of financial position as follows: Under current assets 6,549 5,362 Under non-current assets 243 473 $ 6,792 $ 5,835 December 31, 2018 2017 U.S. dollars in thousands Other receivables: Institutions $ 181 $ 330 Advances to suppliers 187 51 Employees 91 121 Prepaid expenses 556 170 Miscellaneous 3 13 $ 1,018 $ 685 The Group’s exposure to credit risk, currency risk and impairment loss in respect of trade and other receivables is described in Note 20.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2018
Classes of current inventories [abstract]
INVENTORIES	NOTE 4 – INVENTORIES December 31, 2018 2017 U.S. dollars in thousands Raw materials and auxiliary materials $ 1,158 $ 969 Work in process 277 214 Finished products 800 1,077 $ 2,235 $ 2,260

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT Computers Equipment Office Leasehold Total U.S. dollars in thousands Cost: Balance as of January 1, 2018 $ 1,947 $ 1,093 $ 467 $ 317 $ 3,824 Additions 62 434 9 9 514 Balance as of December 31, 2018 2,009 1,527 476 326 4,338 Accumulated depreciation: Balance as of January 1, 2018 1,632 649 319 202 2,802 Depreciation 63 205 26 29 323 Balance as of December 31, 2018 1,695 854 345 231 3,125 Depreciated balance as of December 31, 2018 $ 314 $ 673 $ 131 $ 95 $ 1,213 Cost: Balance as of January 1, 2017 $ 1,883 $ 750 $ 459 $ 317 $ 3,409 Additions 64 349 21 4 438 Disposals - (6 ) (13 ) (4 ) (23 ) Balance as of December 31, 2017 1,947 1,093 467 317 3,824 Accumulated depreciation: Balance as of January 1, 2017 1,570 409 255 167 2,401 Depreciation 62 240 71 37 410 Disposals - - (7 ) (2 ) (9 ) Balance as of December 31, 2017 1,632 649 319 202 2,802 Depreciated balance as of December 31, 2017 $ 315 $ 444 $ 148 $ 115 $ 1,022 The Group has assets that have been fully depreciated and are still in use. As of December 31, 2018 and 2017, the original cost of such assets is $2,928 thousand and $2,614 thousand, respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
INTANGIBLE ASSETS	NOTE 6 – INTANGIBLE ASSETS Computer Capitalized Marketing Total U.S. dollars in thousands Cost: Balance as of January 1, 2018 $ 746 $ 716 $ 375 $ 1,837 Additions 23 90 - 113 Balance as of December 31, 2018 769 806 375 1,950 Accumulated amortization: Balance as of January 1, 2018 678 507 375 1,560 Amortization for the year 38 54 - 92 Balance as of December 31, 2018 716 561 375 1,652 Amortized balance as of December 31, 2018 $ 53 $ 245 $ - $ 298 Cost: Balance as of January 1, 2017 $ 704 $ 606 $ 375 $ 1,685 Additions 42 110 - 152 Balance as of December 31, 2017 746 716 375 1,837 Accumulated amortization: Balance as of January 1, 2017 602 471 355 1,428 Amortization for the year 76 36 20 132 Balance as of December 31, 2017 678 507 375 1,560 Amortized balance as of December 31, 2017 $ 68 $ 209 $ - $ 277 The capitalized development costs are in respect of the Group’s CloudPAT, a cloud-based information technology platform designed to allow customers to transfer the data of the sleep apnea test results of the Group’s products.

EMPLOYEE BENEFITS

EMPLOYEE BENEFITS	12 Months Ended
	Dec. 31, 2018
Disclosure of information about defined benefit plans [abstract]
EMPLOYEE BENEFITS	NOTE 7 – EMPLOYEE BENEFITS Employee benefits include retirement benefit obligations, short-term benefits and share-based payments. As for retirement benefit obligations, the Group has defined benefit plans for which it contributes to insurance policies. As for share-based payments, see Note 15 and as for benefits to key executives, see Note 21. December 31, 2018 2017 U.S. dollars in thousands Presented as part of current liabilities – accounts payable: Short-term employee benefits $ 222 $ 223 Presented as part of non-current liabilities: Long-term employee benefits $ 159 $ 310 Retirement benefit plans - defined benefit plan 1) Movement in net liabilities for defined benefit plans: Year Ended December 31, 2018 2017 U.S. dollars in thousands Balance at beginning of year $ 310 $ 156 Expense recognized in the statements of operations: Current service costs and interest costs 29 61 Recognized loss including other: Actuarial losses carried to other comprehensive income (166 ) 112 Other movements: Benefits paid (5 ) - Deposits made by the Group (9 ) (19 ) Balance at end of year $ 159 $ 310 2) Expenses recognized in the statements of operations: Year Ended December 31, 2018 2017 U.S. dollars in thousands Current service costs $ 16 $ 21 Interest costs 7 6 Transfer of profits to benefits 28 18 Total $ 51 $ 45 3) The principal actuarial assumptions as of the report date (based on weighted average): December 31, 2018 2017 2016 % % % Discount rate at the end of the year 3.82 2.74 3.35 Future salary growth 3.00 3.27 3.32

CREDIT FACILITY WITH A BANK AND

CREDIT FACILITY WITH A BANK AND CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2018
Borrowings [abstract]
CREDIT FACILITY WITH A BANK AND CONVERTIBLE NOTES	NOTE 8 – CREDIT FACILITY WITH A BANK AND CONVERTIBLE NOTES a. Credit facility with a bank In March 2017, the Company received a bank credit line in a total amount of up to $10 million. The credit line is comprised of a $6 million long-term loan and a $4 million credit facility against trade accounts receivable, based on specific customer invoices. The long-term loan is repayable in equal quarterly installments over three years from the date of the draw and bears annual interest of the quarterly dollar LIBOR rate plus 5.5%. The credit facility bears annual interest of the monthly dollar LIBOR rate plus 4.25%. On January 30, 2018, the terms of the bank credit line were amended such that the exercise period of the loan and the credit facility were extended until February 28, 2019 and January 12, 2019, respectively. The framework of the long-term loan component was changes so that it can be utilized as a long-term loan or as a short-term loan. In addition, the Company undertook that upon the withdrawal of credit, the balance of the cash in the Company’s account with the bank will not be less than 40% of the amount of the outstanding credit actually provided to the Company. As part of the bank credit, the Company issued to the bank warrants exercisable into 798,088 of the Company’s ordinary shares at an exercise price of NIS 1.36 per share (equivalent to $0.36 per share as of December 31, 2018)’ which were initially exercisable until March 28, 2022 (see extension below). The fair value of the warrants was measured using a Black-Scholes valuation model and the cost of $137 thousand was accounted for as an integral part of the effective interest rate of the bank credit. On March 12, 2019, the Company and the bank entered into agreement under which the total credit line to be available under the credit facility increased from $10 million to $15 million, comprised of: (i) up to $9 million in long-term or short-term loan; and (ii) up to $6 million of credit facility against trade accounts receivable. As part of the new agreement, the Company issued to the bank additional warrants exercisable into 399,044 ordinary shares at an exercise price of NIS 1.30 per share (equivalent to $0.36 per share as of the date of grant), which will be exercisable until March 28, 2023. In addition, the Company extended the exercise period of the original warrants from March 28, 2022 to March 28, 2023. The fair value of the additional warrants was measured using a Black-Scholes valuation model and the cost of $62 thousand will be accounted for as an integral part of the effective interest rate of the bank credit. As of December 31, 2018, the Company withdrew $5.0 million out of the bank credit as follows: $ 2.25 million as a short-term loan and $2.75 million as a short-term loan against trade accounts receivable. On February 21, 2019, the Company repaid the above $5.0 million and withdrew again, in the ordinary course of business, $5.0 million from the bank credit, as follows: $2.05 million as a short-term loan and $2.95 million as a short-term loan against trade accounts receivable. The loans are for a period of three months until May 20, 2019. As mentioned above, the Company undertook that upon the withdrawal of credit, the balance of the cash in the Company’s account with the bank will not be less than 40% of the amount of the outstanding credit actually provided to the Company, such that that an amount of $2 million is not currently available for the Company’s current use. b. Convertible notes In March 2013, the Company issued, NIS 72,256 thousand par value convertible notes listed for trading on the TASE for total net proceeds of $19.5 million. The notes matured in two principal repayments on February 28, 2017 and on February 28, 2018, and bore fixed interest at 8.65% per annum, payable semi-annually: on August 28 and on February 28, through February 2018. The net proceeds from the issuance of the convertible notes were split into two components for measurement purposes: (i) a liability component without a conversion feature that is measured at amortized cost according to the effective interest method; and (ii) a conversion option that is an embedded derivative and is measured at fair value at each reporting date. The effective interest rate as of the date of the issuance was 27.7%. The attributed transaction costs were allocated to the different components pro-rata to the amounts of their initial recognition before allocation of the said costs. The notes were convertible, so that each NIS 1.92 par value notes could have been converted into one ordinary share (which, as a result of a rights offering conducted by the Company in December 2015, was adjusted such that every 1.92 NIS par value of the notes could be converted to 1.00904 ordinary shares). On February 28, 2017, the first installment of the notes in a total amount of NIS 38,128 thousand par value (approximately $10,421 thousand) was repaid and on February 28, 2018, the second and last installment of the notes in a total amount of NIS 38,128 thousand par value (approximately $10,940 thousand) was repaid, other than NIS 6.0 million (approximately $1.700 thousand) owed to three shareholders who held notes, of which $500 thousand was repaid to one shareholder in June 2018 and the balance owed to the other two shareholders was invested by them in the private placement described in Note 14b. None of the notes were converted.

PROVISIONS

PROVISIONS	12 Months Ended
	Dec. 31, 2018
Provisions [abstract]
PROVISIONS	NOTE 9 – PROVISIONS Warranties Returns Total U.S. dollars in thousands Balance as of January 1, 2017 $ 93 $ 74 $ 167 Provisions made during the year 135 91 226 Provisions reversed during the year (27 ) - (27 ) Provisions realized during the year (101 ) (82 ) (183 ) Balance as of December 31, 2017 100 83 183 Provisions made during the year 86 81 167 Provisions reversed during the year (5 ) - (5 ) Provisions realized during the year (62 ) (68 ) (130 ) Balance as of December 31, 2018 $ 119 $ 96 $ 215

OTHER ACCOUNTS PAYABLE

OTHER ACCOUNTS PAYABLE	12 Months Ended
	Dec. 31, 2018
Trade and other payables [abstract]
OTHER ACCOUNTS PAYABLE	NOTE 10 – OTHER ACCOUNTS PAYABLE December 31, 2018 2017 U.S. dollars in thousands Employees $ 1,403 $ 1,117 Institutions 319 339 Interest payable 11 326 Deferred revenues and advances from customers 255 193 Other 75 23 $ 2,063 $ 1,998 For information about the Group’s exposure to currency and liquidity risks in respect of the payables balances, see Note 20.

DERIVATIVES

DERIVATIVES	12 Months Ended
	Dec. 31, 2018
Derivative Instrument [Abstract]
DERIVATIVES	NOTE 11 – DERIVATIVES Composition December 31, 2018 2017 U.S. dollars in thousands Liabilities The conversion component in the convertible notes $ - $ 96 Viola Warrants (non-traded)* 371 2,315 Warrants (Series 4) (traded) issued in the 2015 rights offering* 71 464 $ 442 $ 2,875 * See Note 14c. All of the above derivatives have either a conversion price or an exercise price that are denominated in NIS, a currency different than the functional currency of the Company and as a result are accounted for as a derivative financial instrument measured at fair value through profit or loss on each reporting date and constitute a liability. The following parameters were used in the calculation of the fair value of the above derivatives, using the binomial model: December 31, 2018 2017 Discount rate for notes which were fully repaid on February 28, 2018 (yield to maturity of the notes) - 104.18 % The discount rate of the Viola Warrants and Warrants (Series 4) (risk free interest) 0.30 % 0.11 % Share price (in NIS) 1.280 1.340 Standard deviation of the share price 54.59 % 56.13 % The fair value of the Viola Warrants and the Warrants (Series 4) (see Note 14c) as of December 31, 2015 and during the nine month period ended September 30, 2016 was measured at quoted market value of the Warrants (Series 4), due to the fact that the Viola Warrants and the Warrants (Series 4) are essentially identical in their conditions. Starting with the fourth quarter of 2016 and until December 31, 2018, the Company believed that there was no active market for the traded Warrants (Series 4) primarily due to an ongoing gradual decline in the frequency and volume of trading in such warrants with significant variance in the transactions prices of the warrants without a corresponding material change in the share price, and often with a negative correlation between the change in the share price and the change in the warrants price. Consequently, the Company estimated the fair value of the Viola Warrants and the Warrants (Series 4) as of December 31, 2016 and for periods thereafter based on observable market data, directly or indirectly, based on the binomial model and based on relevant parameters of the terms of the Viola Warrants and the Warrants (Series 4).

COMMITMENTS

COMMITMENTS	12 Months Ended
	Dec. 31, 2018
Disclosure Of Commitments [Abstract]
COMMITMENTS	NOTE 12 – COMMITMENTS a. Obligation to pay royalties to the Israeli Government’s Innovation Authority (“IIA”) The Company has received royalty-bearing grants sponsored by the IIA for the support of research and development activities of the Endo PAT3000 product (the development of which was discontinued before its completion with no sales to date). However, according to the IIA, the Company must pay royalties on all sales of all of the Company’s cardiology products, and not only for sales of the Endo PAT3000 and/or its technology, up to the total amount of $1,046 thousands. The Company accrued for the royalties’ obligation once the grants became repayable, although the Company is in discussions with the IIA regarding the Company’s obligation to pay royalties on products other than the supported Endo PAT3000. b. Lease commitments The Group has non-cancelable lease agreements for buildings and vehicles. Minimum lease commitments expected under these operating leases are as follows: Year Ending December 31, U.S. dollars 2019 $ 847 2020 720 2021 452 2022 54 Such minimum, lease payments include $319 thousand, $333 thousand, and $181 thousand for the years ending December 31, 2019, 2020 and 2021, respectively, relating to a lease agreement which was extended in January 2019. See also Note 2u regarding the implementation of IFRS 16 as from January 1, 2019.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Income taxes paid (refund) [abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES a. Corporate tax rates in Israel The tax rates relevant to corporates in Israel in the years 2016 – 2018 were as follows: 2016 – 25%; 2017 – 24%; 2018 – 23%. On December 22, 2016, the Knesset (the Israeli parliament) approved the Economic Efficiency Law (Legislative Amendments to Achieve Budget Targets for the 2017 and 2018 Budget Years), 2016, which stipulates, among other things, the reduction of corporate tax rates from 25% to 23% in two phases. The first phase is to a rate of 24%, starting on January 2017 and the second phase is to a rate of 23% starting on January 2018 and thereafter. b. Benefits under the Investment Encouragement Law Approved enterprise, benefited enterprise and preferred enterprise Most of the production facilities of the Company have been granted “Approved Enterprise”, “Benefited Enterprise” and “Preferred Enterprise” status under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”). The Company is a “Foreign Investors’ Company” as defined by the Investment Law, which means it is entitled to tax benefits for taxable income arising from its Approved, Benefited or Preferred Enterprise status. Since its incorporation the Company incurred significant losses and therefore it did not start benefiting from such status. To be eligible for these tax benefits, one must continue to meet certain conditions stipulated in the Investment Law and its regulations and the criteria set out in the specific certificate of approval. The only material condition applicable to the Company is to meet a minimum threshold (25%) of export sales (i.e., sales outside of Israel). In the event the Company is considered as having failed to comply with these conditions, in whole or in part, the eligibility for the benefits may be canceled and the Company may be required to refund the relevant amount, including inflation adjustments and interest. However, since the Company had accumulated carryforward tax losses of approximately $111 million as of December 31, 2018 (see section d. below), it did not benefit from such tax benefits and does not expect to benefit from such tax benefits in the foreseeable future. Once the Company utilizes all of its accumulated tax losses, it expects to derive tax benefits in Israel relating to its Benefited Enterprise and Preferred Enterprise programs for which it is eligible. A company having an Approved or Benefited Enterprise, like the Company, that distributes a dividend from income that was tax exempt, will be required in the tax year of the dividend distribution to pay corporate tax on the amount of the dividend distributed (including the company tax required as a result of the distribution) at the corporate tax rate that would have been applicable to it in the year the income was generated if it had not been exempt from tax. c. Taxation of Non-Israeli subsidiaries Subsidiaries incorporated outside of Israel are assessed for tax under the tax in their countries of residence. The primary tax rates applicable to the non-Israeli subsidiaries in the Group are: U.S. – federal tax rate of 35% during 2016 and 2017, and 21% during 2018 and thereafter. The reduction did not have a material impact on the tax expenses of the U.S. subsidiary in the years ended December 31, 2018 and 2017; The Netherlands – tax rate of 20% during 2017 (the year in which the Netherlands subsidiary of the Company was formed) and 2018; Japan – tax rate of 23.4% during 2016 and 2017 and 23.2% during 2018. Tax expenses in the statements of operations mainly refer to operations of the subsidiaries in the U.S., the Netherlands and Japan. The Company does not pay taxes in Israel, as it has tax losses carryforward to future years. No deferred tax asset was recognized in respect of those carryforward tax losses, in the absence of expected utilization thereof in the foreseeable future. The Company did not include a calculation of the theoretical tax due to the fact that the total tax expenses in the statements of operations are not material. d. Carryforward tax losses The Company has carryforward tax losses (including carryforward research and development expenses) as of December 31, 2018, amounting to $111 million. e. Tax assessment The Company has not received final tax assessments since its incorporation. The Company has self-assessments deemed to be final through the 2013 tax year‎.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2018
Equity [abstract]
EQUITY	NOTE 14 – EQUITY a. Ordinary shares and additional paid-in capital Year Ended December 31, 2018 2017 2016 Number of shares in thousands Issued and outstanding share capital (ordinary shares): Outstanding shares at the beginning of the year 264,495 262,917 259,581 Shares issued in private placements during the year 22,014 - 2,976 Shares issued in exercise of stock options during the year 1,107 1,578 360 Outstanding at the end of the year 287,616 264,495 262,917 Authorized 750,000 750,000 750,000 The rights of the ordinary shares include voting rights at the general meeting of shareholders, the rights to receive dividends and rights to participate in the distribution of the surplus assets of the Company in the event of liquidation. b. 2018 Private Placement On March 22, 2018, the Company entered into separate securities purchase agreements with Viola Growth II A.V. LP, Viola Growth II (A) LP and Viola Growth II (B) LP (collectively, “Viola”), the Company’s largest shareholder; Medtronic International Technology, Inc. (“Medtronic”), a then major shareholder of the Company; Dr. Giora Yaron (through a company wholly owned by him), the Company’s Chairman of the Board of Directors and a major shareholder, and various funds affiliated with three Israeli institutional investors, Yelin Lapidot Mutual Funds Management Ltd., a major shareholder; Meitav Dash Investments Ltd., and The Phoenix Holdings Ltd. On May 27, 2018, following approval by the Company’s shareholders of the private placement contemplated by these securities purchase agreements, the Company completed the transaction and issued to the investors a total of 22,013,893 ordinary shares (representing as of such date approximately 7.7% of the Company’s issued and outstanding shares on a post-issuance basis) at a purchase price of NIS 0.947 per share (equivalent to $0.27 as of May 7, 2018 ) (reflecting a 7% discount on the average share price during the 15 consecutive trading days preceding March 15, 2018 (inclusive), the date of publication of the Company's 2017 financial statements), resulting in aggregate proceeds (before expenses) of NIS 20.8 million (equivalent to approximately $6.0 million). Out of the total NIS 20.8 million investment, Viola, Medtronic and Dr. Giora Yaron, invested NIS 5.2 million, NIS 2.4 million and NIS 2.1 million, respectively. Since then Medtronic transferred the shares issued to it to MS Pace LP, a limited partnership. c. Investment agreement with Viola and the rights offering to the Company’s shareholders On August 26, 2015, the Company entered into a share purchase agreement with Viola. On November 5, 2015 (and, as a second stage of the transaction, on February 1, 2016), following approval by the Company’s shareholders of the transactions contemplated by the share purchase agreement with Viola (the “Viola Transaction”), the Company issued to Viola, in the aggregate for these two closings, 66,876,907 ordinary shares at a purchase price of NIS 1.449 per share (equivalent to $0.38), resulting in aggregate proceeds (before expenses) of NIS 96.9 million (equivalent to approximately $25.2 million). In addition, the Company issued to Viola warrants exercisable into up to 33,438,454 ordinary shares (the “Viola Warrants”) for no additional consideration. The Viola Warrants are not listed for trading. The Viola Warrants are exercisable at an exercise price of (i) for the first 21 months following their issuance, NIS 1.642 per share (equivalent to $0.44 as of December 31, 2018); and (ii) for the remainder of their term, NIS 1.745 per share (equivalent to $0.47 as of December 31, 2018), in each case, subject to adjustments. The Viola Warrants expire on the earlier of: (i) the passage of 42 months following their issuance (i.e., on May 4, 2019); (ii) in the event of a public offering with a pre-money valuation of the Company of at least at $250 million; or (iii) in the event of a merger or sale of the Company which reflects a company value of at least $250 million and the result of which will be that the shareholders in the Company before said event will hold less than the majority of voting rights in the surviving company. In December 2015, as part of a rights offering to its shareholders (other than Viola), the Company issued 12,876,303 ordinary shares at a price of NIS 1.449 per share (equivalent to $0.37), resulting in aggregate proceeds (before expenses) of NIS 18.7 million (equivalent to approximately $4.7 million). In addition, the Company issued to the subscribing shareholders warrants exercisable into up to 6,438,152 ordinary shares (“Warrants (Series 4)”) for no additional consideration. The Warrants (Series 4) were listed on the TASE. Each Warrant (Series 4) is exercisable at an exercise price of (i) for the first 21 months following their issuance, NIS 1.642 per share (equivalent to $0.44 as of December 31, 2018) and (ii) for the remainder of their term, NIS 1.745 per share (equivalent to $0.47 as of December 31, 2018), in each case, subject to adjustments. The net considerations of the issuance of shares and warrants as part of the Viola Transaction and the rights offering were attributed first to the liability component (warrants) and the remaining amount was attributed to the equity component (shares). The issuance costs, in both transactions, are attributed to the shares, the Viola Warrants and the Warrants (Series 4) according to the consideration attributed to each of the components. The issuance costs were deducted from the consideration attributed to the shares. The issuance costs attributed to the Viola Warrants and the Warrants (Series 4) were immediately credited to the statements of operations as financial expenses.

SHARE-BASED PAYMENTS

SHARE-BASED PAYMENTS	12 Months Ended
	Dec. 31, 2018
Disclosure Of Share Based Payments [Abstract]
SHARE-BASED PAYMENTS	NOTE 15 – SHARE-BASED PAYMENTS a. Description of share-based payment arrangements and grants: 1) Performance-based options Unvested performance-based options as of December 31, 2015 were cancelled and replaced on January 21, 2016 with new grants of options and restricted share units (“RSUs”) that are either contingent upon the continued employment only or are also contingent on meeting performance criteria, as detailed in (2) below. 2) Options and RSUs with service conditions and market conditions On January 21, 2016, the Company’s Board of Directors approved a new share-based plan for options and RSUs for key employees that will vest on January 21, 2020 (or earlier in case of an acceleration event), if the share price is at least NIS 2.13 (equivalent to $0.57 as of December 31, 2018) (the “First Trigger Price”), at which time 50% of the RSUs will vest and if the share price is NIS 4.24 (equivalent to $1.13 as of December 31, 2018), 100% will vest. In the range between these two share prices, a relative quantity will vest. An acceleration event is defined as an event in which all the issued and outstanding share capital of the Company (including by way of a merger in which the Company’s shareholders prior to the merger will hold less than 10% of the issued and outstanding share capital and voting rights in the company surviving the merger) is sold for consideration reflecting a price per share that is not lower than NIS 2.13 (equivalent to $0.57 as of December 31, 2018). The above vesting is also contingent upon continued employment. On March 14, 2018, the Company’s Board of Directors approved a change of the First Trigger Price from NIS 2.13 (equivalent to $0.57 as of December 31, 2018) to NIS 1.70 (equivalent to $0.45 as of December 31, 2018) and a change of the January 21, 2020 vesting date to December 20, 2020. On May 23, 2018 the Company’s shareholders approved such changes with respect to the portion of such options and RSUs granted to the Company’s President and Chief Executive Officer (the “CEO”). Such change triggered a new measurement of the fair value of the options and the RSUs. The fair value of the above changes was $239 thousand. The assessment has been executed using a Monte-Carlo Simulation. 3) Options to key employees, employees and directors with only service condition On January 21, 2016, the Company’s Board of Directors, as part of the share-based plan described in (2) above, also approved a grant of options that will vest as followed: 25% will vest and become exercisable one year following the date of grant and the remaining 75% will vest and become exercisable in 12 equal quarterly portions, beginning on the first anniversary of the date of grant. Grants to other employees not participating in the key employees share-based plan, usually vest over four years, as follows: 2/3 will vest and be exercisable two years following the date of grant, and the remaining 1/3 will vest and become exercisable in four equal quarterly portions, at the end of each calendar quarter commencing on the second anniversary of the date of grant. Options granted to directors during the years ended December 31, 2016, 2017 and 2018, were usually divided into three tranches, each equal to 33% of the amount of options granted. The allotment and the vesting period for the first tranche began on the date of grant; the allotment and the vesting period for the second tranche will begin on first anniversary of the date of grant; and the allotment and the vesting period for the third tranche will begin on the third anniversary of the date grant. Each tranche vests in four equal portions annually over four years. The exercise price for each tranche is set on the date of allotment and is based on the average market price of the ordinary share prior to such allotment date plus 10%. The grants to directors were measured on the grant date for all three tranches using the binomial model. The option data in d. below include only options already allotted. 4) Grants of options and RSUs under the January 2016 plan Grants in the reported years In March 2016, the Company granted to (i) the CEO options exercisable into 3,620,834 ordinary shares in lieu of all the options granted in the past that have not yet vested, and (ii) 16 other employees options exercisable into 3,755,847 ordinary shares in lieu of all the options granted in the past that have not yet vested. In addition, the terms of options exercisable into 741,314 ordinary shares granted in the years ended December 31, 2014 and 2015 to other employees were modified, such that the performance conditions of their exercise were cancelled and their vesting period has been extended. The said replacement was handled as a change in the conditions in accordance with IFRS 2, Share-based Payment In May 2016, the Company granted 1,759,999 options to directors. In September 2016, the Company granted to employees 1,114,129 options and 72,545 RSUs. In February 2017, the Company granted 711,000 options to 15 employees. In May 2017, the Company granted 440,000 options to directors and 100,000 options were granted to a consultant. In September 2017, the Company granted 2,281,218 options and 362,858 RSUs to 11 employees. In addition, 100,000 options were granted to a consultant. In March 2018, the Company granted 1,802,512 options and 229,534 RSUs to 20 employees and officers. In addition, 263,681 options and 49,032 RSUs were granted to a consultant. In August 2018, the Company granted 530,137 options and 17,160 RSUs to12 employees. Grants subsequent to December 31, 2018 On January 30, 2019, the Company’s Board of Directors approved the grant of (i) options exercisable into 1,968,954 ordinary shares at exercise price ranging between NIS 1.30 and NIS 1.43 (equivalent to between $0.35 and $ 0.39 as of January 30, 2019) per share, which expire between 2024 and 2026; and (ii) 339,495 performance-based RSUs, to employees of the Company and its U.S. subsidiary. All said RSUs are without an exercise price. b. Measurement of fair value of share-based payments The fair value of the options with service conditions granted to employees, directors and consultants is measured according to the Black-Scholes valuation model. The fair value of options and RSUs granted to officers and key employees where vesting is made on the basis of the increase in the Company’s share price and is measured by implementing the Monte Carlo Simulation. The options granted to directors but which have not yet been allocated, nor set an exercise price, were priced using the binomial model. Following are the parameters used to measure the fair value on the date of grant of share-based awards during the year ended December 31, 2018: Options with only Options with RSUs The number of shares arising from the exercise of the options (in thousands) 1,313 1,283 296 The parameters included when calculating fair value: The share price (at the grant date) (in NIS) 1.10 – 1.25 1.10 – 1.25 1.10 – 1.25 The exercise price (in NIS) 1.12 – 1.29 1.02 – 1.17 0.00 – 0.30 Expected volatility (weighted average) 55% – 58 % 55% – 56 % 55% – 56 % Expected lifetime (weighted average) 3.5– 4.0 years 4.7– 5.7 years N/A Risk-free interest rate 0.91% – 1.13 % 1.27% – 1.46 % N/A Expected dividend rate 0 % 0 % 0 % The expected volatility was determined based on the historical volatility of the share price. The expected lifetime of the options is determined in accordance with management’s estimation of the duration of the employees’ holdings of such awards, given their position in the Company and the Company’s past experience with respect to employee attrition. The risk-free interest rate is based on interest rates of Israeli government bonds denominated in NIS, whose remaining period is equal to the expected lifetime of the options. c. Extension of the exercise period of options granted to the CEO and to officers and key employees of the Company and its subsidiaries On March 21, 2017, the Company’s Board of Directors resolved to extend by five years, till January 20, 2026, the exercise period of a total of 18,890,695 options, consisting of 3,699,208 options with service conditions and 15,191,487 options with service conditions and market conditions, granted to officers and key employees of the Company and its subsidiaries. There was no change in the other terms of the options, including the exercise price and the vesting terms. The new exercise period is in line with the Company’s compensation policy which allows an exercise period of up to ten years. On May 14, 2017 the Company’s shareholders approved such extension with respect to the portion of such options granted to the CEO. The fair value of the extension of the exercise period of the options was $475 thousand. The assessment of the fair value of change on the service-based options has been executed using Black-Scholes valuation model. The assessment of the fair value of change on the options with service conditions and market conditions has been executed using a Monte-Carlo Simulation. The assumptions used are detailed below: Service Performance Expected volatility 57.6 % 57.6 % Average lifetime (in years) 4.8 – 5.9 8.8 Risk free interest rate 0.91% - 1.36 % 2.0 % Expected dividends rate 0 % 0 % d. Reconciliation of outstanding options and RSU’s The number of options and RSUs and the weighted average exercise price for every option or RSU: Year Ended December 31, 2018 2017 2016 Number of Range of Number of Range of Number of Range of Outstanding at beginning of year 35,892,484 0.00 – 2.50 40,178,148 0.00 – 2.50 24,316,648 0.10 – 2.50 Granted during the year 3,312,056 0.00 – 1.29 4,105, 076 0.00 – 1.68 28,180,067 0.00 – 1.55 Forfeited and expired during the year (2,305,527 ) - (6,825,690 ) - (11,962,761 ) - Exercised during the year (1,096,800 ) 023 – 0.51 (1,565,050 ) 0.23 (355,806 ) 0.10 - 0.48 Outstanding at end of year * 35,802,213 0.00 - 2.50 35,892,484 0.00 - 2.50 40,178,148 0.00 - 2.50 Exercisable at end of year 10,114,392 0.23 - 2.50 9,716,559 0.23 - 2.50 12,319,881 0.23 - 2.50 * Including: Options with service conditions only 15,661,344 Options with service conditions and market conditions 16,699,449 RSUs 3,441,420 Total 35,802,213 As a result of the grant of options and RSUs, the Company recorded for the years ended December 31, 2018, 2017 and 2016, a non-cash expense of $1,021 thousand, $1,294 thousand and $1,776 thousand, respectively. The balance of expenditure amounting to $1,090 thousand will be recorded by the Company over the remaining vesting period of the options and RSUs. The total share-based compensation expenses relating to all of the Company’s share-based awards recognized for the years ended December 31, 2018, 2017 and 2016 were included in items of the consolidated statements of operations, as follows: Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Cost of revenues $ 10 $ 9 $ 30 Selling and marketing expenses 295 336 429 Research and development expenses 104 87 257 General and administrative expense 612 740 1,060 Financial expenses from notes and loans - 122 - $ 1,021 $ 1,294 $ 1,776 The weighted average share price upon exercise of the options, for options exercised in the year ended December 31, 2018 and 2017 and 2016 was $0.35, $0.35 and $0.34, respectively. The weighted average remaining contractual life of the options outstanding as of December 31, 2018, 2017 and 2016 was 5.74 years, 6.23 years and 4.22 years, respectively.

REVENUES

REVENUES	12 Months Ended
	Dec. 31, 2018
Revenue [abstract]
REVENUES	NOTE 16 – REVENUES The Company operates in one business sector. The following is a breakdown of revenues according to product groups. Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands WatchPAT and other related services $ 22,384 $ 18,105 $ 15,697 Endo PAT and other related services 1,805 2,596 2,743 $ 24,189 $ 20,701 $ 18,440 The following is a breakdown of revenues on the basis of geographical regions (based on the geographical location of the customer). Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands United States and Canada $ 17,582 $ 14,764 $ 13,343 Japan 3,374 2,965 2,161 Europe 1,885 1,746 1,542 Asia Pacific (excluding Japan) 849 759 1,017 Israel 281 260 268 Others 218 207 109 $ 24,189 $ 20,701 $ 18,440 The majority of the Company’s long lived assets are in Israel. Revenue from major customers Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Customer A $ 4,571 $ 3,622 $ 3,549 Customer B 3,229 2,621 2,119 Customer C 2,870 2,510 2,096 $ 10,670 $ 8,753 $ 7,764

COST OF REVENUES

COST OF REVENUES	12 Months Ended
	Dec. 31, 2018
Disclosure Of Cost Of Sales [Abstract]
COST OF REVENUES	NOTE 17 – COST OF REVENUES Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Raw materials, auxiliary materials, subcontractors (including changes in inventories) $ 2,538 $ 1,767 $ 2,173 Payroll and related expenses (including share-based payment) 1,806 1,956 1,749 Shipping 443 500 386 Depreciation and amortization 255 190 124 Other 684 589 547 $ 5,726 $ 5,002 $ 4,979

FINANCIAL INCOME AND EXPENSES

FINANCIAL INCOME AND EXPENSES	12 Months Ended
	Dec. 31, 2018
Disclosure Of Financial Income And Expenses [Abstract]
FINANCIAL INCOME AND EXPENSES	NOTE 18 – FINANCIAL INCOME AND EXPENSES Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Financial income from cash and investments: In respect of investments in bank deposits and marketable securities * $ 93 $ 1,389 $ 547 Other financial income 151 202 169 $ 244 $ 1,591 $ 716 Financial expenses from notes, loans and other: Convertible notes* $ 393 $ 4,427 $ 4,610 Short-term bank loan 316 - - Short-term shareholders’ loans 85 - - Other financial expenses 359 427 185 Exchange rate differences 8 30 (35 ) $ 1,161 $ 4,884 $ 4,760 Gain (loss) on derivative financial instruments: Gain on revaluation to fair value of the warrants embedded in the convertible notes $ 96 2,141 1,567 Gain (loss) on revaluation to fair value of warrants 2,337 1,784 (1,783 ) $ 2,433 $ 3,925 $ (216 ) * Including the effect of changes in the exchange rate of the NIS against the dollar.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Dec. 31, 2018
Earnings per share [abstract]
LOSS PER SHARE	NOTE 19 – LOSS PER SHARE a. Basic loss per share The computation of basic loss per share was based on the net loss attributable to ordinary shares divided by the weighted average number of ordinary shares outstanding. Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Net loss attributed to the ordinary shares $ (1,729 ) $ (5,301 ) $ (14,403 ) Weighted average number of ordinary shares Year Ended December 31, 2018 2017 2016 Number of shares in thousands Balance at the beginning of the year 264,495 262,917 259,581 The effect of private placement and rights offering 12,908 - 2,716 The effect of exercise of options into shares 262 1,192 245 Weighted average number of ordinary shares used in computation of basic loss per share 277,665 264,109 262,542 b. Diluted loss per share The computation of diluted loss per share was based on the net loss attributed to the ordinary shares divided by the weighted average number of ordinary shares outstanding, after adjustment for all potentially dilutive ordinary shares, as follows: Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Net loss used in computation of basic earnings per share $ (1,729 ) $ (5,301 ) $ (14,403 ) Changes in the fair value of the Viola warrants and Warrants (Series 4), which are classified as a liability (2,434 ) (1,785 ) - Net loss attributed to the ordinary shares (diluted) $ (4,163 ) $ (7,086 ) $ (14,403 ) Weighted average number of ordinary shares (diluted) Year Ended December 31, 2018 2017 2016 Number of shares in thousands Weighted average number of ordinary shares used in computation of basic loss per share 277,665 264,109 262,542 Effect of the exercise of the Viola warrants and Warrants (Series 4) 43,246 39,877 - Weighted average number of ordinary shares used in computation of diluted loss per share per share 320,911 303,986 262,542 In the calculation of the weighted average number of ordinary shares (diluted) for the year ended December 31, 2018, 3,369,797 shares in respect of convertible notes, 33,438,454 shares in respect of the Viola Warrants, 32,412,199 shares in respect of options and 3,441,420 shares in respect of RSUs granted to employees, directors and consultants were not included, due to their anti-dilutive effect. In the calculation of the weighted average number of ordinary shares (diluted) for the year ended December 31, 2017, 23,588,582 shares in respect of convertible notes, 32,719,056 shares in respect of options and 3,242,632 shares in respect of RSUs granted to employees, directors and consultants were not included, due to their anti-dilutive effect. In the calculation of the weighted average number of ordinary shares (diluted) for the year ended December 31, 2016, 40,075,289 shares in respect of convertible notes, 33,438,454 shares in respect of the Viola Warrants, 6,438,152 shares in respect of Warrants (Series 4) and 36,779,259 shares in respect of options and 3,398,889 shares in respect of RSUs granted to employees, directors and consultants were not included, due to their anti-dilutive effect.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS	NOTE 20 –FINANCIAL INSTRUMENTS This note provides qualitative information regarding the exposure to each of the following risks, and the Group’s objectives, policy and processes relating to measurement of such risks. Quantitative disclosure is provided throughout these consolidated financial statements. Credit risk As of December 31, 2018 and 2017, the maximum exposure to credit risk is represented by the balance of financial assets. Management has developed policies for the authorization of credit to customers. The accounting exposure to credit risk is monitored constantly according to the behavior of payment of the debtors. Credit is assigned on a customer-by-customer basis and is subject to assessments which consider the customers’ payment capacity, as well as past behavior regarding due dates, balances past due and delinquent accounts. Approximately 44%, 42% and 42%, respectively, of the Group’s revenues in the years ended December 31, 2018, 2017 and 2016, arise from sales to single customers. Other than this, there are no other concentrations of credit risk. The Group’s revenues are primarily derived from sales to customers in the U.S., Japan and Europe. Management regularly monitors trade receivables and the financial statements include specific provisions for doubtful debt, which properly reflect, in the opinion of management, the inherent loss in debt whose collection is in doubtful. The Group limits its exposure to credit risk by investing exclusively in bank deposits. The Group realized its investments in securities at fair value in January and February 2018, close to the date of repayment of the convertible notes. As of December 31, 2017 the investment includes investment in corporate and Israeli government NIS-denominated bonds. Following is the composition of investments in marketable securities as of December 31, 2017: U.S. Government bonds – NIS linked to the Israeli CPI $ 368 Government bonds – NIS 838 Corporate bonds – NIS linked to the Israeli CPI 1,008 Corporate bonds –NIS 777 Current account 182 $ 3,173 The maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investments, as of the report date, by geographic locations was as follows: December 31, 2018 2017 U.S. dollars in thousands Israel $ 5,378 $ 9,581 United States and Canada 6,337 5,815 Asia Pacific (including Japan) 936 817 Europe 998 909 Other 194 27 $ 13,843 $ 17,149 Aging of receivables and impairment and weighted average loss rate: December 31, 2018 December 31, 2017 Weighted Gross Impairment Gross Impairment % U.S. dollars in thousands U.S. dollars in thousands Not in arrears 1.2 $ 5,464 $ 64 $ 4,502 $ - In arrears up to three months 1.2 1,030 12 1,160 - In arrears up to six months 1.2 221 3 200 35 In arrears up to 12 months 17.5 188 32 71 63 In arrears over 12 months 100.0 159 159 442 442 $ 7,062 $ 270 $ 6,375 $ 540 Movements in the allowance for impairment of receivables during the year were as follows: Year Ended December 31, 2018 2017 U.S. dollars in thousands Balance at beginning of year $ 540 $ 450 Recognized impairment loss 104 147 Bad debt (374 ) (57 ) Balance at end of year $ 270 $ 540 Liquidity risk The Group’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group’s reputation. The Group ensures that it has sufficient cash on hand for payment of expected operating expenses, including any amounts required to fulfill financial obligations. In addition to cash flows provided by its operating activities, in order to meet the Company’s overall liquidity needs for operations, servicing debt and funding capital expenditures, the Company relies on cost-cutting and operating improvements to optimize capacity utilization and minimizing loss, as well as borrowing under credit facilities, proceeds of debt and equity offerings, Below is an analysis of contractual maturities of financial liabilities, including estimated interest payments, as of December 31, 2018 and 2017: Carrying Contractual Up to 6 6-12 months 1-2 years 2-5 years Over 5 U.S. dollars in thousands December 31, 2018 Non-derivative financial liabilities Short-term bank loans $ 5,000 $ 5,065 $ 5,065 $ - $ - $ - $ - Trade payables 1,517 1,517 1,517 - - - - Other long-term liabilities 1,052 1,052 - - - - 1,052 Other accounts payable 2,767 2,767 2,668 99 - - - Total $ 10,336 $ 10,401 $ 9,250 $ 99 $ - $ - $ 1,052 December 31, 2017 Non-derivative financial liabilities Convertible notes, including current maturities and accrued interest $ 11,022 $ 11,473 $ 11,473 $ - $ - $ - $ - Trade payables 1,262 1,262 1,262 - - - - Other long-term liabilities 948 948 - - - - 948 Other accounts payable 2,714 2,714 2,536 178 - - - Total $ 15,946 $ 16,397 $ 15,271 $ 178 $ - $ - $ 948 Equity Risk Changes in the fair value of the Viola Warrants and the Warrants (Series 4) that are denominated in a currency other than the Company’s functional currency affect the statements of operations. However, they do not imply any risk or variability in cash flows, considering that through their exercise, the Company will settle the aforementioned derivatives through issuance of its own shares rather than in cash. As discussed in Note 8b, the convertible notes were fully repaid in February 2018, and, together with the repayment of the notes, the conversion component expired. As to the remaining derivatives being measured at fair value (the Viola Warrants and the Warrants (Series 4), which will expire in May 2019 and their exercise price is substantially higher that the share price as of December 31, 2018), a hypothetical, instantaneous, increase or decrease of 10% in the market price of the Company’s share price, with all other variables held constant, is expected to have an immaterial impact on the Company’s net loss in 2019. Foreign Currency risk The Group is exposed to foreign currency risk with respect to sales, purchases, payroll and services expenses and loans denominated in non-dollar currencies (primarily NIS, but also Euro and Japanese yen) used by the companies in the Group. The currencies in which most expenses are denominated are the dollar, NIS, Euro and Japanese yen. Most of the Group’s revenues are denominated in its functional currency (the dollar) and some in Euro, whereas the Group’s payroll expenses in Israel are denominated in NIS. Therefore, the Group is exposed to fluctuations in the dollar/NIS and dollar/Euro exchange rates and strives to mitigate currency risk by maintaining liquid investments and cash positions in short-term NIS-denominated deposits, in NIS and in Euro. The Group’s exposure to the Israeli CPI and foreign currency risk is as follows: Currency different from dollar Dollars NIS NIS linked Euro Other Non- Total U.S. dollars in thousands December 31, 2018 Assets Cash and cash equivalents $ 4,088 $ 1,885 $ - $ 426 $ 72 $ - $ 6,471 Trade receivables (including long-term trade receivables) 6,236 229 - 327 - - 6,792 Accounts receivable 247 32 - 2 - 737 1,018 Inventories - - - - - 2,235 2,235 Long-term restricted deposits 109 190 - - - - 299 Long-term prepaid expenses - - - - - 66 66 Property and equipment and intangible assets - - - - - 1,511 1,511 10,680 2,336 - 755 72 4,549 18,392 Liabilities Trade payables 714 798 - 5 - - 1,517 Employee benefits - - - - - 381 381 Provisions - - - - - 215 215 Other accounts payable (including accrued expenses) 1,965 761 - 50 - 321 3,097 Sort-term bank loan 5,000 - - - - - 5,000 Financial derivatives - 442 - - - - 442 Other long-term accounts payable 947 105 - - - - 1,052 8,626 2,106 - 55 - 917 11,704 Total exposure in the statements of financial position in respect of financial assets and financial liabilities $ 2,054 $ 230 $ - $ 700 $ 72 $ 3,632 $ 6,688 December 31, 2017 Assets Cash and cash equivalents $ 2,337 $ 5,124 $ - $ 160 $ 22 $ - $ 7,643 Marketable securities - 1,797 1,376 - - - 3,173 Trade receivables (including long-term trade receivables) 4,952 194 - 689 - - 5,835 Accounts receivable 137 45 - 3 - 500 685 Inventories - - - - - 2,260 2,260 Long-term restricted deposits 108 205 - - - - 313 Long-term prepaid expenses - - - - - 69 69 Property and equipment and intangible assets - - - - - 1,299 1,299 7,534 7,365 1,376 852 22 4,128 21,277 Liabilities Trade payables 382 833 - 47 - - 1262 Employee benefits - - - - - 533 533 Provisions - - - - - 183 183 Other accounts payable (including accrued expenses) 1,877 1,117 - 70 - 339 3,403 Convertible notes - 10,696 - - - - 10,696 Financial derivatives - 2,875 - - - - 2,875 Other long-term accounts payable 905 - 43 - - - 948 3,164 15,521 43 117 - 1,055 19,900 Total exposure in the statements of financial position in respect of financial assets and financial liabilities $ 4,370 $ (8,156 ) $ 1,333 $ 735 $ 22 $ 3,073 $ 1,377 Sensitivity analysis A stronger dollar against the following currencies at the end of each reporting period, and an increase in the Israeli CPI would have increased (decreased) equity and net income/loss by the following amounts (after-tax). The following analysis is based on changes to exchange rates, which the Group believes to be reasonably possible as of the end of the reported year. This analysis assumes all other variables, especially interest rates, remain constant. December 31, 2018 Equity Profit (loss) U.S. dollars in thousands An increase in the exchange rate of the following currencies against the dollar: NIS/dollar by 5% $ 12 $ 12 Euro/dollar by 5% 35 35 The weakening of these currencies against the dollar at a similar rate as of December 31, 2018 had a similar effect, albeit in the opposite direction, assuming that all other variables remain constant. December 31, 2017 Equity Profit (loss) U.S. dollars in thousands An increase in the exchange rate of the following currencies against the dollar: NIS/dollar by 5% $ (340 ) $ (340 ) Euro/dollar by 5% 37 37 The weakening of these currencies against the dollar at a similar rate as of December 31, 2017 had a similar effect, albeit in the opposite direction, assuming that all other variables remain constant. Fair value of financial instruments measured at fair value, for disclosure purposes only The carrying amount of the cash and cash equivalents, trade receivables, other accounts receivable, bank deposits, pledged deposits, trade payables, and other accounts payable and derivatives is identical or approximate to their fair values due to the lifetime of these items. The fair value of other financial assets and liabilities and their carrying amounts, as presented in the statements of financial position, are as follows: December 31, 2018 December 31, 2017 Carrying amount Fair value Carrying amount Fair value U.S. dollars in thousands Liabilities: Convertible notes $ - $ - $ **11,118 $ *11,283 Liability in respect of royalties to the IIA and other government institutions 1,151 490 1,072 430 $ 1,151 $ 490 $ 12,190 $ 11,713 * Including interest payable, but excluding the fair value of the embedded warrants. ** Quoted market price on the TASE. Fair value hierarchy of financial instruments measured at fair value The following table shows an analysis of the financial instruments measured at fair value using the valuation method. December 31, 2018 Level 1 Level 3 Total U.S. dollars in thousands Financial instruments - derivative instruments $ - $ 442 $ 442 December 31, 2017 Level 1 Level 3 Total U.S. dollars in thousands Financial instruments - marketable securities $ 3,173 $ - $ 3,173 Financial instruments - derivative instruments - 2,875 2,875 The change from the opening balance to the closing balance of the financial instruments measured at fair value, categorized within Level 3 hierarchy, in the years ended December 31, 2018 and 2017, respectively, was caused by the revaluation to fair value of the derivatives in the amount of $2,433 thousand and $3,925 thousand as described in Note 18.

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2018
Disclosure of transactions between related parties [abstract]
RELATED PARTIES	NOTE 21 – RELATED PARTIES a. Compensation Compensation to key executives includes: Year Ended December 31, 2018 2017 2016 Number Amount Number Amount Number Amount U.S. dollars in U.S. dollars in U.S. dollars in Employee compensation 7 $ 1,835 7 $ 1,384 6 $ 1,590 Share-based payment 7 702 7 1,083 6 1,168 $ 2,537 $ 2,467 $ 2,758 Compensation to directors who are not employed by the Company: Year Ended December 31, 2018 2017 2016 Number of Amount Number of Amount Number of Amount U.S. dollars in U.S. dollars in U.S. dollars in Total benefits to directors not employed by the Company 8 $ 284 9 $ 306 9 $ 278 Year Ended December 31, December 31, 2018 2017 2016 2018 2017 Transaction amounts Carrying amount U.S. dollars in thousands U.S. dollars in thousands Key executives (including directors) of the Company $ 2,821 $ 2,773 $ 3,035 $ 341 $ 1,147 b. Capital reserve for transactions with shareholders Any difference between the nominal value - i.e., the cash amount received - of the loans provided by shareholders, acting in the capacity of shareholders, and their fair value on initial recognition is reflected in equity as a shareholder contribution. Upon an early extinguishment of such debt, any cost incurred as a result of the early extinguishment is reflected in equity as a shareholder distribution. c. Insurance and indemnification of key management personnel The Company’s directors and officers are covered by a directors’ and officers’ liability insurance policy. In addition, the Company has undertaken to enter into indemnification agreements with each of its directors and officers undertaking to indemnify them to the fullest extent permitted by law. d. Marketing agreement with a former controlling shareholder in the Company In 2014, the Company entered into a co-marketing agreement with Medtronic, Inc. (“Medtronic”) (which at the time was a controlling shareholder) that was subsequently amended in 2015. According to the agreement (as amended), Medtronic was granted exclusive rights to co-market, with the Company, the Company’s WatchPAT products within the Company’s Total Sleep Solution framework to electrophysiologists (physicians who specialize in cardiology arrhythmias) in the U.S. Pursuant to this agreement, Medtronic markets WatchPAT as part of a comprehensive solution offered by Medtronic to physicians. The agreement is currently renewable automatically for 30 day-periods, unless earlier terminated by either party upon 14 days prior notice. In the years ended on December 31, 2018, 2017 and 2016, the Company recognized revenues from sales to customers (third parties) under this agreement in the amount of approximately $207 thousand, $307 thousand and $177 thousand, respectively. The total sales commissions to Medtronic in these years under this agreement totaled approximately $41 thousand, $61 thousand and $35 thousand, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2018
Disclosure of non-adjusting events after reporting period [abstract]
SUBSEQUENT EVENTS	NOTE 22 – SUBSEQUENT EVENTS: a. 2019 Private Placement On January 16, 2019 and January 28, 2019, the Company entered into separate securities purchase agreements with several U.S. and Israeli accredited investors. Under the securities purchase agreements, the Company undertook to issue to the investors, upon and subject to the closing:, (i) a total of 1,170,707 ADSs, at a price per ADS of $9.55, to the investors (other than the Israeli investor) (the “U.S. Tranche”); and (ii) a total of 10,944,185 ordinary shares to the Israeli investor, at a price per ordinary share of NIS 1.1693 (equivalent to $0.32 as of February 3, 2019) (the “Israeli Tranche”), or, in the aggregate, the Company undertook to issue to the investors a total of 46,115,395 ordinary shares (including ordinary shares underlying the ADSs) representing, as of January 28, 2019, approximately 13.8% of the Company’s issued and outstanding shares on a post-issuance basis, resulting in aggregate proceeds (before expenses) of approximately $14.7 million. The closing of the transaction was subject to listing and other customary conditions, including (i) with respect to the U.S. Tranche, that (a) this registration statement will become effective and (b) the ADSs are eligible for, and have commenced, trading on the Nasdaq Capital Market; and (ii) with respect to the Israeli Tranche, receipt of listing approval by the TASE. On February 3, 2019, the Company completed the private placement of the Israeli Tranche and issued to the Israeli investor, 10,994,185 ordinary shares, and on March 6, 2018, the Company completed the private placement of the U.S. Tranche and issued to the investors under the U.S, Tranche a total of 1,170,707 ADSs. Pursuant to the securities purchase agreements, the Company agreed, subject to customary exceptions, not to raise additional funds or issue equity securities until the earlier of 180 days following the closing or an initial public offering of its ADSs. In addition, the Company’s directors and executive offices have entered into customary lockup agreements, whereby each of them agreed not to sell their ordinary shares from January 16, 2019 until the earlier of (i) 180 days following the closing of the U.S. Tranche, (ii) the termination of the securities purchase agreement, or (iii) ten (10) months following the signing (November 15, 2019). The ordinary shares and ADSs issued to the investors are subject to resale restrictions under applicable U.S. and Israeli securities laws. None of the investors were granted registration rights under the securities purchase agreements. The securities purchase agreements contain other customary terms and conditions, including customary representations and warranties of the parties which survive the completion of the transaction until the date on which the investors no longer hold any of the ADSs or shares, as applicable. b. Grant of stock options and RSUs See Note 15a(4). c. Amendment of the bank line of credit See Note 8a.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
International financial reporting standards	a. International financial reporting standards These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). These consolidated financial statements were approved by the Company’s Board of Directors on April 10, 2019.
Reporting and functional currency	b. Reporting and functional currency These consolidated financial statements are presented in U.S. dollars (“dollar” or “$”), which is the Company’s functional currency representing the principal economic environment in which the Company operates, and have been rounded to the nearest thousand unless otherwise indicated.
Basis of measurement	c. Basis of measurement These consolidated financial statements have been prepared on the historical cost basis, except for certain investments and derivatives and other financial instruments measured at fair value through profit or loss, provisions, and assets and liabilities with respect to employee benefits.
Principles of consolidation	d. Principles of consolidation Subsidiaries are entities controlled by the Company. The financial statements of the subsidiaries, which are wholly-owned, are included in the consolidated financial statements of the Company from the date of their incorporation. Intercompany balances and transactions between Group companies are eliminated in consolidation.
Use of estimates and critical assumptions	e. Use of estimates and critical assumptions The preparation of financial statements in accordance with IFRS requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements as well as affect the reported amounts of revenues and expenses during the period. These estimates and assumptions are reviewed on an ongoing basis using available information. Actual results could differ from these estimates and assumptions. The items subject to significant estimates and assumptions by management include share-based compensation, the measurement of financial instruments at fair value, the fair value of the embedded warrant component of convertible notes, and the fair value of warrants where there is no active market.
Foreign currency transactions and balances	f. Foreign currency transactions and balances Transactions in foreign currency are translated to the respective functional currency of the Group entities at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between the amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency, translated at the exchange rate at the end of the year. Non-monetary assets and liabilities denominated in foreign currency that are measured in terms of historical cost, are translated using the exchange rate at the date of the transaction. Foreign currency differences arising from translation into the functional currency are recognized in the statements of operations.
Changes in accounting policies - initial application of new standards and interpretations	g. Changes in accounting policies - initial application of new standards and interpretations (1) IFRS 9 (2014), Financial Instruments As from January 1, 2018, the Group adopted IFRS 9, which replaces IAS 39, Financial Instruments: Recognition and Measurement IFRS 9 sets forth the guidance relating to the classification and measurement of financial assets and liabilities, the accounting for expected credit losses of financial assets and commitments to extend credits, as well as the requirements for hedge accounting. As described in section i below, the adoption of IFRS 9 did not have a material effect on the Company’s financial statements. (2) IFRS 15, Revenues from Contracts with Customers As from January 1, 2018, the Group adopted IFRS 15, which provides new guidance on revenue recognition. The Group elected to adopt IFRS 15, using the cumulative impact approach, with an adjustment to the balance of accumulated deficit as of January 1, 2018 and without restating the comparative figures. IFRS 15 introduces a new five step model for recognizing revenue from contracts with customers: (a) Identifying the contract with the customer. (b) Identifying distinct performance obligations in the contract. (c) Determining the transaction price. (d) Allocating the transaction price to distinct performance obligations. (e) Recognizing revenue when the performance obligations are satisfied. As to the revenue recognition policy applied by the Group as from January 1, 2018 under IFRS 15, see section q below. As part of the initial adoption of IFRS 15, the Group elected to implement the following exemptions: (a) Application of the cumulative impact approach only for contracts that have not been concluded at the date of transition; and (b) Examining the aggregate impact of changes in the contract that occurred before the date of initial application, instead of an examination of each change separately. For the year ended December 31, 2018, there was no impact to revenue and to cost of revenue as result of the adoption of IFRS 15. As of January 1, 2018 and December 31, 2018, the Group had an immaterial effect on its financial statements as a result of reclassifying contract liabilities, which were previously deducted from accounts receivables, as current liabilities in respect of contract assets that the rights in their respect are unconditional, together with a corresponding increase to deferred revenue in accordance with the guidance of IFRS 15.
Cash and Cash Equivalents	h. Cash and Cash Equivalents Cash and cash equivalents are comprised of available amounts of cash and cash equivalents, mainly represented by highly-liquid short-term investments (with original maturities of three months or less), which are readily convertible into known amounts of cash, and which are not subject to significant risks of changes in their values.
Financial instruments:	i. Financial instruments: The accounting policy applied as from January 1, 2018 As from January 1, 2018, the Group applies the following accounting policies under IFRS 9, see also section g(1) above as to the effect of initial adoption. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition, based on the business model objectives and nature of the investment: amortized cost; fair value through other comprehensive income (loss) – investment in equity instruments; or fair value through profit and loss. Debt instrument is classified to amortized cost category if it meets both of the following conditions: - It is held within a business model whose objective is to hold assets so as to collect contractual cash flows; and - The contractual terms of the financial asset give rise to cash flows representing solely payments of principal and interest (“SPPI”) on the principal amount outstanding on specified dates. A debt instrument can also be classified to fair value through other comprehensive income category if its business model objective is achieved by both collecting contractual cash flows and selling financial assets, and it meets the SPPI criteria as above. In certain cases, a debt instrument can be designated at initial acquisition to fair value through profit or loss. As applicable to the Group, the Group’s debt instruments that are classified to amortized cost category include: deposits, trade and other accounts receivable (including long-term trade receivables). These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss. The Group’s debt instruments that were classified at fair value through other comprehensive income include debt marketable securities. These securities were realized in the beginning of 2018. The Group classifies its financial assets to fair value through profit and loss category, when: - It is a debt instrument that does not meet the above criteria; - It is an investment at fair value through other comprehensive income (loss) in equity securities; or - It is part of a portfolio of financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis. These assets are subsequently measured at fair value. As of December 31, 2018, the Group did not have such assets. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. Impairment of financial assets IFRS 9 replaces the impairment model of IAS 39 (“incurred loss” model), with an ‘expected credit loss’ (“ECL”) model. The model applies to financial assets measured at amortized cost, investments in debt instruments measured at fair value through other comprehensive income, contract assets (as defined in IFRS 15) and lease receivables, but not to investments in equity instruments. Under the new model, the Group assesses the expected credit losses in advance as follows: - for debt instruments that have low credit risk or for which no significant deterioration has occurred in their credit quality since initial recognition – the impairment loss will be assessed based on the expected credit loss in the period during the 12 months following the reporting date; and - for debt instruments for which a significant deterioration has occurred in their credit quality since initial recognition and their credit risk is not low, the impairment loss will be assessed based on the remaining life of the instrument. The Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables and contract assets. Non-derivative financial liabilities Non-derivative financial liabilities include loans and borrowings from banks and others, convertible notes, and trade and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Liabilities, which are convertible into shares, denominated in a currency different than the functional currency of the Company or linked to the Israeli Consumer Price Index (the “Israeli CPI”), constitute a hybrid instrument presented in full as a financial liability. For measurement, the instrument is separated into two components: (i) a liability component with no conversion feature, which is classified to amortized cost category, and (ii) a conversion option, which constitutes an embedded derivative accounted for as a derivative financial instrument at fair value and is measured through the statements of operations as part of “Financial income (expenses), net”. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) and the liability component of the hybrid instrument above are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled. Substantial modification in terms of debt instruments An exchange of debt instruments having substantially different terms, is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Furthermore, a substantial modification of the terms of an existing financial liability, or an exchange of debt instruments having substantially different terms between an existing borrower and lender, are accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability at fair value. In such cases the entire difference between the amortized cost of the original financial liability and the fair value of the new financial liability is recognized in profit or loss as financing income or expense. The terms are substantially different if the discounted present value of the cash flows according to the new terms, including any commissions paid, less any commissions received and discounted using the original effective interest rate, is different by at least ten percent (10%) from the discounted present value of the remaining cash flows of the original financial liability. Upon the swap of debt instruments with equity instruments, equity instruments issued at the extinguishment and de-recognition of all or part of a liability, are a part of “consideration paid” for purposes of calculating the gain or loss from de-recognition of the financial liability. The equity instruments are initially recognized at fair value, unless fair value cannot be reliably measured – in which case the issued instruments are measured at the fair value of the derecognized liability. Any difference between the amortized cost of the financial liability and the initial measurement amount of the equity instruments is recognized in profit or loss under financial income or expenses. Non-substantial modification in terms of debt instruments In a non-substantial modification in terms (or exchange) of debt instruments, the new cash flows are discounted using the original effective interest rate, and the difference between the present value of the new financial liability and the present value of the original financial liability is recognized in profit or loss. Offset of financial instruments Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Issuance of bundle of securities The consideration received from the issuance of a bundle of securities is attributed initially to financial liabilities measured each period at fair value, and then to financial liabilities measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the grant of the consideration from the issuance of the bundle, as described above. Derivative financial instruments The Group recognizes all derivative instruments as assets or liabilities in the statements of financial position at their estimated fair values, and the changes in such fair values are recognized in the statements of operations within “Financial income (expenses), net” for the period in which they occur. During the reported years, the Group did not have derivatives designated as hedges. The Group reviews its contracts to identify the existence of embedded derivatives. Identified embedded derivatives in hybrid contracts where the host is not an asset, are analyzed to determine if they need to be separated from the host contract and recognized in the statements of financial position as assets or liabilities, applying the same valuation rules used for other derivative instruments. Fair value measurements Under IFRS, fair value represents an “Exit Value”, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, considering the counterparty’s credit risk in the valuation. The concept of Exit Value is premised on the existence of a market and market participants for the specific asset or liability. When there is no market and/or market participants willing to make a market, IFRS establishes a fair value hierarchy that gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: · Level 1— Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group has the ability to access at the measurement date. A quote price in an active market provides the most reliable evidence of fair value and is used without adjustment to measure fair value whenever available. · Level 2— Inputs, other than quoted prices in active markets, that are observable for the asset or liability, either directly or indirectly, and are used mainly to determine the fair value of securities, investments or loans that are not actively traded. · Level 3— Unobservable inputs for the asset or liability are used when little or no market data is available. The Group used unobservable inputs to determine fair values, to the extent there are no Level 1 or Level 2 inputs, in valuation models such as Black-Scholes, binomial, discounted cash flows or multiples, including risk assumptions consistent with what market participants would use to arrive at fair value. The accounting policy applied in periods prior to January 1, 2018 Trade accounts receivable and other accounts receivable Trade accounts receivable and other accounts receivable are classified as loans and receivables and are recorded at their amortized cost representing the net present value of the consideration receivable or payable as of the transaction date. Due to their short-term nature, the Group initially recognizes these receivables at the original invoiced amount. Allowances for doubtful accounts were recognized based on incurred loss estimates against general and administrative expenses. Long-term trade receivables and other investments Long-term trade receivables are initially recognized at their amortized cost. Subsequent changes in net present value are recognized in the statements of operations as part of “Financial income (expenses), net”. Investments in financial instruments held for trading as well as those investments available-for-sale, are recognized at their estimated fair value, in the first case through the statements of operations as part of “Financial income (expenses), net” and in the second case, changes in valuations are recognized as part of “Other comprehensive income (loss)” for the year within “Capital reserve” until their time of disposition, when all valuation effects accrued in equity are reclassified to “Financial income (expenses), net” in the statements of operations. These investments are tested for impairment upon the occurrence of a significant adverse change or at least once a year during the last quarter. Debt and other financial obligations Bank loans and notes payable, are recognized at their amortized cost. Interest accrued on financial instruments is recognized within “Other accounts payable and accrued expenses” against financial expenses. Direct costs incurred in debt issuances or borrowings, adjust the carrying amount of the related debt and are amortized as interest expense as part of the effective interest rate of each instrument over its maturity. These costs include commissions and professional fees. In the statements of cash flows, interest received and interest paid on bank loans and notes payable are presented in cash flows from operating activities. Liabilities, which are convertible into shares, denominated in a currency different than the functional currency of the Company or linked to the Israeli CPI, constitute a hybrid instrument presented in full as a financial liability. For measurement, the instrument is separated into two components: (i) a liability component with no conversion feature, which is measured at amortized cost according to the effective interest method, and (ii) a conversion option, which constitutes an embedded derivative accounted for as a derivative financial instrument at fair value and is measured through the statements of operations as part of “Financial income (expenses), net”. Issuance of bundle of securities The consideration received from the issuance of a bundle of securities is attributed initially to financial liabilities measured each period at fair value, and then to financial liabilities measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the grant of the consideration from the issuance of the bundle, as described above. Derivative financial instruments The Group recognizes all derivative instruments as assets or liabilities in the statements of financial position at their estimated fair values, and the changes in such fair values are recognized in the statements of operations within “Financial income (expenses), net” for the period in which they occur. During the reported years, the Group did not have derivatives designated as hedges. The Group reviews its contracts to identify the existence of embedded derivatives. Identified embedded derivatives are analyzed to determine if they need to be separated from the host contract and recognized in the statements of financial position as assets or liabilities, applying the same valuation rules used for other derivative instruments.
Inventories	j. Inventories Inventories are valued using the lower of cost and net realizable value. The cost of inventories is based on the “moving-average” method, including expenditures incurred in acquiring the inventories and the costs incurred in bringing it to its existing location and condition. The Group analyzes its inventory balances to determine if, as a result of internal events, such as physical damage, or external events, such as technological changes or market conditions, certain portions of such balances have become obsolete or impaired. When an impairment situation arises, the inventory balance is adjusted to its net realizable value, whereas, if an obsolescence situation occurs, the inventory obsolescence reserve is increased. In both cases, these adjustments are recognized against the results of the period. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs to complete and sell the inventories.
Property and equipment	k. Property and equipment Property and equipment are recognized at their acquisition or construction cost, as applicable, less accumulated depreciation and accumulated impairment losses. Depreciation of property and equipment is recognized as part of operating expenses, and is calculated using the straight-line method over the estimated useful lives of the assets. As of December 31, 2018, the average useful lives by category of property and equipment were as follows: % Office furniture and equipment 10 Equipment and devices for leasing and for internal use 15 Computers 33 Leasehold improvements are amortized over the shorter of the lease term and their useful lives. Depreciation methods and useful lives are reviewed at the end of each reporting year and adjusted if appropriate.
Intangible assets	l. Intangible assets The Group capitalizes intangible assets acquired, as well as costs incurred in the development of certain intangible assets for internal use, when future economic benefits associated are identified and there is evidence of control over such benefits. Intangible assets are recognized at their acquisition or development cost, as applicable. All of the Group’s intangible assets are definite life intangible assets, and are amortized on straight-line basis over the useful life of the asset, which on average is approximately three years. Expenditure on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of operations when incurred. Development activities are related to a plan to produce new products or processes, or to significantly improve existing products or processes. Development expenditure is capitalized only if: (i) the expenditure can be measured reliably; (ii) the product or process is technically and commercially feasible; and (iii) future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use. Other development expenditure is recognized in the statements of operations as incurred. In subsequent periods, capitalized development expenditure is measured at cost less accumulated amortization and any accumulated impairment losses. Amortization methods and useful lives are reviewed at the end of each reporting year and adjusted if appropriate.
Impairment of property and equipment, intangible assets of definite life and other investments	m. Impairment of property and equipment, intangible assets of definite life and other investments These assets are tested for impairment upon the occurrence of factors such as the occurrence of a significant adverse event, changes in the Group’s operating environment or in technology, as well as expectations of lower operating results, in order to determine whether their carrying amounts may not be recovered. An impairment loss is recorded in the statements of operations for the period within “Other expenses, net”, for the excess of the asset’s carrying amount over its recoverable amount, corresponding to the higher of the fair value less costs to sell the asset, and the asset’s value in use, the latter represented by the net present value of estimated cash flows related to the use and eventual disposal of the asset. No impairment loss was recorded during the reported years.
Provisions	n. Provisions The Group recognizes provisions when it has a legal or constructive obligation resulting from past events, whose resolution would imply cash outflows or the delivery of other resources owned by the Group. Obligations or losses related to contingencies are recognized as liabilities in the statements of financial position only when present obligations exist resulting from past events and it is probable to result in an outflow of resources and the amount can be measured reliably. Otherwise, a qualitative disclosure is included in the notes to the financial statements. The provisions are determined by discounting the future cash flows at a pre-tax interest rate, reflecting the current market estimates of the time value of the money and the specific risks of the liability without weighting the Group’s credit risk. The carrying value of the provision is then adjusted in every period so as to reflect the passage of time and the adjustment amount is credited to financial expenses.
Post-employment benefits	o. Post-employment benefits The costs of defined contribution plans are recognized in the operating results as they are incurred. Liabilities arising from such plans are settled through cash transfers to the employees’ retirement accounts with insurance companies or with funds managed by others, without generating future obligations. The majority of the Israeli employees are under defined contribution plans. The rest of the Israeli employees are under defined benefit plans. The costs associated with defined benefit plans are recognized as services are rendered, based on actuarial estimations of the benefits’ present value with the advice of external actuaries.
Share-based payment transactions	p. Share-based payment transactions The grant-date fair value of share-based payment awards granted to employees and directors is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees and directors become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest. For share-based payment awards with non-vesting conditions or with market performance vesting conditions, the grant date fair value of the share-based payment awards is measured to reflect such conditions, and therefore the Group recognizes an expense in respect of the awards whether or not the conditions have been met. The fair value at the time of grant of share-based payment awards to consultants and service providers are recognized over the consultants’ and the service providers’ period of service against an increase in equity. The fair value of the services is calculated on the basis of the fair value of the awards and not on the basis of the fair value of the services, since it is not possible to reliably estimate the fair value of the services rendered. The Group elected to record the increase in equity against salary expense directly to accumulated deficit.
Revenue recognition	q. Revenue recognition The accounting policy applied as from January 1, 2018 As from January 1, 2018, the Group applies the following accounting policies under IFRS 15. See also section g(2) above as to the effect of initial adoption. The Group recognizes revenues when the customer obtains control over the products or services that have been secured, net of provision for returns and discounts. The revenue is measured according to the amount of consideration that the Group expects to be entitled to in return for the transfer of products or services promised to the customer, other than amounts collected in favor of third parties. The Group recognizes estimated sales discounts as a reduction of sales in the same period revenue is recognized. The Group adjusts reserves to reflect differences between estimated and actual. The Group estimates its sales returns reserve based on historical return rates and analysis of specific accounts. When the Group sells its products through distributors, revenue is being recognized upon delivery of the product to the distributor, as the distributors does not have the right to return and the control over the products is transferred at this point in time. Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the products or services that will be transferred; (c) The Group can identify the payment terms for the products or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the products or services transferred to the customer, will be collected. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: (i) the Group has no remaining obligations to transfer products or services to the customer and any consideration promised by the customer has been received and cannot be returned; or (ii) the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations The Group identifies products or services promised to the customer as being distinct performance obligations when the customer can benefit from the products or services on their own or in conjunction with other readily available resources and the Group’s promise to transfer the products or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer products or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the products or services with other products or services promised in the contract into one integrated outcome that is the purpose of the contract. Products or services that are not considered as being distinct are grouped together as a single performance obligation. The revenue from each such performance obligation is recognized upon transfer of control over the promised products or services to customer. In general, the Group allocates the transaction price to the identified performance obligations in the contract, based on the relative stand-alone selling prices when the products or services are sold separately. In cases where the products or services are not sold separately, for example, in the case of installations or training, the Group establishes the stand-alone selling price assigned to that performance obligation, based on estimated costs plus a reasonable margin. Significant financing component in installment sales is separated in determining the transaction price. As applicable to the Group, revenues from sales agreements consisting of multiple products or services, such as devices, consumables, access to the CloudPAT application, WatchPAT Direct logistic services and support, extended warranty and other service agreements, are separated into different performance obligations, based on their relative fair values, and revenue is separately recognized for each performance obligation. The Group recognizes revenue from renting its products over the rent term, in conformity with the agreement with the customer. Since 2015, the Group has focused on offering Total Sleep Solution (“TSS”) to the cardiology market through various business models; however, the Test as a Service (“TaaS”), also known as Cost per Test (“CPT”) model, is the primary model the Group utilized to date. In the TaaS model, the medical practice or physician ordering the TaaS pays a fixed fee per home sleep apnea test (“HSAT”) that includes all the components associated with the test, including the disposable biosensor, hardware rental fees and access to the Group’s CloudPAT platform. Under the TaaS model, some rent agreements of the WatchPAT devices are made for a period of one to two years. The rental fees are separated under the relative fair value approach. In some cases, the Group handles sale transactions of these devices as a finance lease and recognizes revenue in respect of the products supplied at the commencement date of the lease. When these transactions include multiple performance obligations, revenue is recognized based on the relative stand-alone selling prices of each performance obligation in the transaction when they are sold separately. Operating lease arrangements offer customers theft or loss warranty, for which if elected, the Group makes appropriate provision for their replacement. Satisfaction of performance obligations Revenue is recognized when the Group satisfies a performance obligation by transferring control over the promised products or services to the customer. Sale of devices and disposables are generally recognized upon shipment. Services (including extended warranty) are recognized ratably over time. Contract assets and liabilities A contract asset is recognized when the Group has a right to consideration for products or services it transferred to the customer that is conditional on other than the passing of time, such as future performance of the Group. Contract assets are classified as receivables when the rights in their respect become unconditional. A contract liability is recognized when the Group has an obligation to transfer products or services to the customer for which it received consideration (or the consideration is payable) from the customer. An asset and liability relating to the same contract are presented on a net basis in the statement of financial position. On the other hand, a contract asset and contract liability deriving from different contracts are presented on a gross basis in the statement of financial position. The accounting policy applied in periods prior to January 1, 2018 Revenue is measured at the fair value of the consideration received or receivable, net of returns and discounts. The Group recognizes revenue from the sale of its products, net of provision for returns, when persuasive evidence exists (usually in the form of an executed sales agreement) that the significant risks and rewards of ownership of the products have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of products can be estimated reliably, there is no continuing management involvement with the products, and the amount of revenue can be measured reliably. Revenue is recognized when title to the products and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Group or any matters requiring customer acceptance. The timing of the transfer of risks and rewards may be upon shipment or upon delivery to the customer site, based on the contract terms or legal requirements. The Group recognizes estimated sales discounts as a reduction of sales in the same period revenue is recognized. The Group adjusts reserves to reflect differences between estimated and actual. The Group estimates its sales returns reserve based on historical return rates and analysis of specific accounts. Revenues from sales agreements consisting of multiple elements, such as devices, consumables, access to the CloudPAT application, WatchPAT Direct logistic services and support and other service agreements, are separated into different components and are separately recognized for each component. A component constitutes a separate accounting unit if and only if it has value, separately, for the customer. Components not separated, are grouped together. The revenue from each such component is recognized upon fulfillment of the conditions for recognition of revenue, based on the nature of the component, i.e., as products or as services. In general, the Group determines the fair value for each element, based on selling prices when the product or service is sold separately. In cases where the components are not sold separately, for example, in the case of installations or training, the Group establishes the value assigned to this element, based on estimated costs plus a reasonable margin. The Group recognizes revenue from leasing its products over the lease term, in conformity with the agreement with the customer. In some cases, the Group handles sale transactions in these devices as finance lease and recognizes revenues in respect of the products supplied, based on their relative fair value compared to all the components in the transaction. When the Group sells its products through distributors, revenue is being recognized upon delivery of the product to the distributor, as the distributors does not have the right to return and the material risks and rewards inherent to the ownership of the products are transferred at this time.
Income taxes	r. Income taxes The effects reflected in the statements of operations for income taxes include the amounts incurred during the period and the amounts of deferred income taxes, determined according to the income tax law applicable to each Group company. Consolidated deferred income taxes represent the addition of the amounts determined in each Group company by applying the enacted statutory income tax rate to the total temporary differences resulting from comparing the book and taxable values of assets and liabilities, considering tax assets such as loss carryforwards and other recoverable taxes, to the extent that it is probable that future taxable profits will be available against which they can be utilized. The measurement of deferred income taxes at the reporting period reflects the tax consequences that follow the manner in which the Group expects to recover or settle the carrying amount of its assets and liabilities. Deferred income taxes for the period represent the difference between balances of deferred income taxes at the beginning and the end of the period. Deferred income tax assets and liabilities relating to different tax jurisdictions are not offset. According to IFRS, all items charged or credited directly in shareholders’ equity or as part of other comprehensive income or loss for the period are recognized net of their current and deferred income tax effects. The effect of a change in enacted statutory tax rates is recognized in the period in which the change is officially enacted. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable income will be available against which they can be utilized.
Loss per share	s. Loss per share The Group presents basic and diluted loss per share data for its ordinary shares. Basic loss per share is calculated by dividing the net loss attributable to holders of ordinary shares of the Company, by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all potentially dilutive ordinary shares, which include convertible notes and options and warrants issued to shareholders employees, directors and consultants.
Transactions with controlling shareholders	t. Transactions with controlling shareholders Assets and liabilities, which are subject to a transaction with a controlling shareholder, are measured at fair value upon the transaction date. As the transaction is on the equity level, the Company recognized the difference between fair value and the consideration from the transaction in its equity.
New standard not yet adopted:	u. New standard not yet adopted: IFRS 16, Leases IFRS 16 supersedes IAS 17, Leases In addition, IFRS 16 allows the lessee to apply the definition of a lease in one of the following two alternatives consistently to all leases: retrospective application for all lease agreements, i.e., a reevaluation of the existence of a lease for each contract separately or alternatively the application of a practical relief. The provisions of IAS 17 and International Financial Reporting Interpretations Committee (“IFRIC”) 4, “Determining Whether an Arrangement Contains a Lease”, defines criteria with respect to the existing agreements as of the date of initial application of IFRS 16. In addition, IFRS 16 provides new and broader disclosure requirements than those existing today. IFRS 16 is effective for annual periods beginning on or after January 1, 2019. IFRS 16 includes various alternatives for the implementation of the transitional provisions, so that one of the following alternatives can be chosen consistently for all leases at initial application: full retrospective application, or application of the cumulative effect, i.e., implementation of IFRS 16 (with the possibility of several concessions) for the first time with adjustments to the opening balance of retained earnings as of that date. The manner of implementation of IFRS 16 and expected effects The Group intends to adopt IFRS 16 as of January 1, 2019 in the cumulative effect approach, while adjusting the retained earnings as of January 1, 2019. The Group elected to adopt the relief of not separating non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component. The Group also decided to adopt the relief of not applying the requirement to recognize a right-of-use asset and a lease liability with regard to leases whose lease period ends within 12 months from the date of the initial adoption. Expected effect The Group intends to choose to apply the transitional provision according to which it will recognize the IFRS 16 implementation date of the lease liability according to the present value of the balance of the future lease payments, discounted at the lessee’s incremental interest rate on that date and concurrently recognize a right-of-use lease asset, which were recognized as an asset or liability prior to the IFRS 16 implementation date. As a result, implementation of IFRS 16 is not expected to have an effect on retained earnings as of the date of initial application The Group is required to recognize at the initial implementation date a right-of-use asset and lease liability for all leases in which it is found that it has the right to control the use of identified assets for a specified period of time. These changes are expected to result in an increase of $1.1 million in the balance of the right-of-use assets and a corresponding increase in the balance of the lease liability as of January 1, 2019. In addition, in January 2019, the Group signed an addendum to its lease agreement in Caesarea, Israel whereby it extended the lease period of its offices in Israel for an additional 30-month period, until July 2021. This addendum will result in an increase of $0.8 million in the balance of the right-of-use assets and a corresponding increase in the balance of the lease liability as of January 20, 2019. Accordingly, depreciation and amortization expenses in respect of an asset will be recognized, and the need to record impairment in respect of a right-of-use asset will be examined in accordance with the provisions of IAS 36, Impairment of Assets

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Schedule of estimated useful lives of property, plant and equipment	% Office furniture and equipment 10 Equipment and devices for leasing and for internal use 15 Computers 33

TRADE AND OTHER RECEIVABLES (Ta

TRADE AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2018
Trade and other receivables [abstract]
Schedule of trade and other receivables	December 31, 2018 2017 U.S. dollars in thousands Trade receivables: Open accounts $ 7,040 $ 6,048 Checks receivable 22 327 7,062 6,375 Less - allowance for doubtful accounts 270 540 6,792 5,835 Is presented in the statements of financial position as follows: Under current assets 6,549 5,362 Under non-current assets 243 473 $ 6,792 $ 5,835 December 31, 2018 2017 U.S. dollars in thousands Other receivables: Institutions $ 181 $ 330 Advances to suppliers 187 51 Employees 91 121 Prepaid expenses 556 170 Miscellaneous 3 13 $ 1,018 $ 685

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2018
Classes of current inventories [abstract]
Schedule of inventories	December 31, 2018 2017 U.S. dollars in thousands Raw materials and auxiliary materials $ 1,158 $ 969 Work in process 277 214 Finished products 800 1,077 $ 2,235 $ 2,260

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of property and equipment	Computers Equipment Office Leasehold Total U.S. dollars in thousands Cost: Balance as of January 1, 2018 $ 1,947 $ 1,093 $ 467 $ 317 $ 3,824 Additions 62 434 9 9 514 Balance as of December 31, 2018 2,009 1,527 476 326 4,338 Accumulated depreciation: Balance as of January 1, 2018 1,632 649 319 202 2,802 Depreciation 63 205 26 29 323 Balance as of December 31, 2018 1,695 854 345 231 3,125 Depreciated balance as of December 31, 2018 $ 314 $ 673 $ 131 $ 95 $ 1,213 Cost: Balance as of January 1, 2017 $ 1,883 $ 750 $ 459 $ 317 $ 3,409 Additions 64 349 21 4 438 Disposals - (6 ) (13 ) (4 ) (23 ) Balance as of December 31, 2017 1,947 1,093 467 317 3,824 Accumulated depreciation: Balance as of January 1, 2017 1,570 409 255 167 2,401 Depreciation 62 240 71 37 410 Disposals - - (7 ) (2 ) (9 ) Balance as of December 31, 2017 1,632 649 319 202 2,802 Depreciated balance as of December 31, 2017 $ 315 $ 444 $ 148 $ 115 $ 1,022

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Schedule of intangible assets	Computer Capitalized Marketing Total U.S. dollars in thousands Cost: Balance as of January 1, 2018 $ 746 $ 716 $ 375 $ 1,837 Additions 23 90 - 113 Balance as of December 31, 2018 769 806 375 1,950 Accumulated amortization: Balance as of January 1, 2018 678 507 375 1,560 Amortization for the year 38 54 - 92 Balance as of December 31, 2018 716 561 375 1,652 Amortized balance as of December 31, 2018 $ 53 $ 245 $ - $ 298 Cost: Balance as of January 1, 2017 $ 704 $ 606 $ 375 $ 1,685 Additions 42 110 - 152 Balance as of December 31, 2017 746 716 375 1,837 Accumulated amortization: Balance as of January 1, 2017 602 471 355 1,428 Amortization for the year 76 36 20 132 Balance as of December 31, 2017 678 507 375 1,560 Amortized balance as of December 31, 2017 $ 68 $ 209 $ - $ 277

EMPLOYEE BENEFITS (Tables)

EMPLOYEE BENEFITS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of information about defined benefit plans [abstract]
Schedule of share-based payments	December 31, 2018 2017 U.S. dollars in thousands Presented as part of current liabilities – accounts payable: Short-term employee benefits $ 222 $ 223 Presented as part of non-current liabilities: Long-term employee benefits $ 159 $ 310
Schedule of movement in net liabilities defined benefit plans	Year Ended December 31, 2018 2017 U.S. dollars in thousands Balance at beginning of year $ 310 $ 156 Expense recognized in the statements of operations: Current service costs and interest costs 29 61 Recognized loss including other: Actuarial losses carried to other comprehensive income (166 ) 112 Other movements: Benefits paid (5 ) - Deposits made by the Group (9 ) (19 ) Balance at end of year $ 159 $ 310
Schedule of expenses recognized in statements of operations	Year Ended December 31, 2018 2017 U.S. dollars in thousands Current service costs $ 16 $ 21 Interest costs 7 6 Transfer of profits to benefits 28 18 Total $ 51 $ 45
Schedule of principal actuarial assumptions	December 31, 2018 2017 2016 % % % Discount rate at the end of the year 3.82 2.74 3.35 Future salary growth 3.00 3.27 3.32

PROVISIONS (Tables)

PROVISIONS (Tables)	12 Months Ended
	Dec. 31, 2018
Provisions [abstract]
Schedule of provisions	Warranties Returns Total U.S. dollars in thousands Balance as of January 1, 2017 $ 93 $ 74 $ 167 Provisions made during the year 135 91 226 Provisions reversed during the year (27 ) - (27 ) Provisions realized during the year (101 ) (82 ) (183 ) Balance as of December 31, 2017 100 83 183 Provisions made during the year 86 81 167 Provisions reversed during the year (5 ) - (5 ) Provisions realized during the year (62 ) (68 ) (130 ) Balance as of December 31, 2018 $ 119 $ 96 $ 215

OTHER ACCOUNTS PAYABLE (Tables)

OTHER ACCOUNTS PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2018
Trade and other payables [abstract]
Schedule of other accounts payables	December 31, 2018 2017 U.S. dollars in thousands Employees $ 1,403 $ 1,117 Institutions 319 339 Interest payable 11 326 Deferred revenues and advances from customers 255 193 Other 75 23 $ 2,063 $ 1,998

DERIVATIVES (Tables)

DERIVATIVES (Tables)	12 Months Ended
	Dec. 31, 2018
Derivative Instrument [Abstract]
Schedule of composition of derivatives	December 31, 2018 2017 U.S. dollars in thousands Liabilities The conversion component in the convertible notes $ - $ 96 Viola Warrants (non-traded)* 371 2,315 Warrants (Series 4) (traded) issued in the 2015 rights offering* 71 464 $ 442 $ 2,875 * See Note 14c.
Schedule of assumptions use to calculate fair value of derivatives	December 31, 2018 2017 Discount rate for notes which were fully repaid on February 28, 2018 (yield to maturity of the notes) - 104.18 % The discount rate of the Viola Warrants and Warrants (Series 4) (risk free interest) 0.30 % 0.11 % Share price (in NIS) 1.280 1.340 Standard deviation of the share price 54.59 % 56.13 %

COMMITMENTS (Tables)

COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Commitments [Abstract]
Schedule of lease commitments	Year Ending December 31, U.S. dollars 2019 $ 847 2020 720 2021 452 2022 54

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [abstract]
Schedule of ordinary shares and additional paid-in capital	Year Ended December 31, 2018 2017 2016 Number of shares in thousands Issued and outstanding share capital (ordinary shares): Outstanding shares at the beginning of the year 264,495 262,917 259,581 Shares issued in private placements during the year 22,014 - 2,976 Shares issued in exercise of stock options during the year 1,107 1,578 360 Outstanding at the end of the year 287,616 264,495 262,917 Authorized 750,000 750,000 750,000

SHARE-BASED PAYMENTS (Tables)

SHARE-BASED PAYMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Share Based Payments [Abstract]
Schedule of measurement of fair value of share-based payments	Options with only Options with RSUs The number of shares arising from the exercise of the options (in thousands) 1,313 1,283 296 The parameters included when calculating fair value: The share price (at the grant date) (in NIS) 1.10 – 1.25 1.10 – 1.25 1.10 – 1.25 The exercise price (in NIS) 1.12 – 1.29 1.02 – 1.17 0.00 – 0.30 Expected volatility (weighted average) 55% – 58 % 55% – 56 % 55% – 56 % Expected lifetime (weighted average) 3.5– 4.0 years 4.7– 5.7 years N/A Risk-free interest rate 0.91% – 1.13 % 1.27% – 1.46 % N/A Expected dividend rate 0 % 0 % 0 %
Schedule of fair value of change on service-based options executed using Black-Scholes valuation model	Service Performance Expected volatility 57.6 % 57.6 % Average lifetime (in years) 4.8 – 5.9 8.8 Risk free interest rate 0.91% - 1.36 % 2.0 % Expected dividends rate 0 % 0 %
Schedule of reconciliation of outstanding options and RSU's	Year Ended December 31, 2018 2017 2016 Number of Range of Number of Range of Number of Range of Outstanding at beginning of year 35,892,484 0.00 – 2.50 40,178,148 0.00 – 2.50 24,316,648 0.10 – 2.50 Granted during the year 3,312,056 0.00 – 1.29 4,105, 076 0.00 – 1.68 28,180,067 0.00 – 1.55 Forfeited and expired during the year (2,305,527 ) - (6,825,690 ) - (11,962,761 ) - Exercised during the year (1,096,800 ) 023 – 0.51 (1,565,050 ) 0.23 (355,806 ) 0.10 - 0.48 Outstanding at end of year * 35,802,213 0.00 - 2.50 35,892,484 0.00 - 2.50 40,178,148 0.00 - 2.50 Exercisable at end of year 10,114,392 0.23 - 2.50 9,716,559 0.23 - 2.50 12,319,881 0.23 - 2.50 * Including: Options with service conditions only 15,661,344 Options with service conditions and market conditions 16,699,449 RSUs 3,441,420 Total 35,802,213
Schedule of share-based compensation expenses relating to share-based awards recognized	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Cost of revenues $ 10 $ 9 $ 30 Selling and marketing expenses 295 336 429 Research and development expenses 104 87 257 General and administrative expense 612 740 1,060 Financial expenses from notes and loans - 122 - $ 1,021 $ 1,294 $ 1,776

REVENUES (Tables)

REVENUES (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue [abstract]
Schedule of breakdown of revenues according to product groups	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands WatchPAT and other related services $ 22,384 $ 18,105 $ 15,697 Endo PAT and other related services 1,805 2,596 2,743 $ 24,189 $ 20,701 $ 18,440
Schedule of breakdown of revenues by geographical regions	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands United States and Canada $ 17,582 $ 14,764 $ 13,343 Japan 3,374 2,965 2,161 Europe 1,885 1,746 1,542 Asia Pacific (excluding Japan) 849 759 1,017 Israel 281 260 268 Others 218 207 109 $ 24,189 $ 20,701 $ 18,440
Schedule of revenue from major customers	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Customer A $ 4,571 $ 3,622 $ 3,549 Customer B 3,229 2,621 2,119 Customer C 2,870 2,510 2,096 $ 10,670 $ 8,753 $ 7,764

COST OF REVENUES (Tables)

COST OF REVENUES (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Cost Of Sales [Abstract]
Schedule of cost of revenues	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Raw materials, auxiliary materials, subcontractors (including changes in inventories) $ 2,538 $ 1,767 $ 2,173 Payroll and related expenses (including share-based payment) 1,806 1,956 1,749 Shipping 443 500 386 Depreciation and amortization 255 190 124 Other 684 589 547 $ 5,726 $ 5,002 $ 4,979

FINANCIAL INCOME AND EXPENSES (

FINANCIAL INCOME AND EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Financial Income And Expenses [Abstract]
Schedule of financial income and expenses	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Financial income from cash and investments: In respect of investments in bank deposits and marketable securities * $ 93 $ 1,389 $ 547 Other financial income 151 202 169 $ 244 $ 1,591 $ 716 Financial expenses from notes, loans and other: Convertible notes* $ 393 $ 4,427 $ 4,610 Short-term bank loan 316 - - Short-term shareholders’ loans 85 - - Other financial expenses 359 427 185 Exchange rate differences 8 30 (35 ) $ 1,161 $ 4,884 $ 4,760 Gain (loss) on derivative financial instruments: Gain on revaluation to fair value of the warrants embedded in the convertible notes $ 96 2,141 1,567 Gain (loss) on revaluation to fair value of warrants 2,337 1,784 (1,783 ) $ 2,433 $ 3,925 $ (216 ) * Including the effect of changes in the exchange rate of the NIS against the dollar.

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings per share [abstract]
Schedule of basic loss per share	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Net loss attributed to the ordinary shares $ (1,729 ) $ (5,301 ) $ (14,403 ) Weighted average number of ordinary shares Year Ended December 31, 2018 2017 2016 Number of shares in thousands Balance at the beginning of the year 264,495 262,917 259,581 The effect of private placement and rights offering 12,908 - 2,716 The effect of exercise of options into shares 262 1,192 245 Weighted average number of ordinary shares used in computation of basic loss per share 277,665 264,109 262,542
Schedule of diluted loss per share	Year Ended December 31, 2018 2017 2016 U.S. dollars in thousands Net loss used in computation of basic earnings per share $ (1,729 ) $ (5,301 ) $ (14,403 ) Changes in the fair value of the Viola warrants and Warrants (Series 4), which are classified as a liability (2,434 ) (1,785 ) - Net loss attributed to the ordinary shares (diluted) $ (4,163 ) $ (7,086 ) $ (14,403 ) Weighted average number of ordinary shares (diluted) Year Ended December 31, 2018 2017 2016 Number of shares in thousands Weighted average number of ordinary shares used in computation of basic loss per share 277,665 264,109 262,542 Effect of the exercise of the Viola warrants and Warrants (Series 4) 43,246 39,877 - Weighted average number of ordinary shares used in computation of diluted loss per share per share 320,911 303,986 262,542

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Schedule of composition of investments in marketable securities	U.S. Government bonds – NIS linked to the Israeli CPI $ 368 Government bonds – NIS 838 Corporate bonds – NIS linked to the Israeli CPI 1,008 Corporate bonds –NIS 777 Current account 182 $ 3,173
Schedule of maximum exposure to credit risk	December 31, 2018 2017 U.S. dollars in thousands Israel $ 5,378 $ 9,581 United States and Canada 6,337 5,815 Asia Pacific (including Japan) 936 817 Europe 998 909 Other 194 27 $ 13,843 $ 17,149
Schedule of aging of receivables and impairment and weighted average loss rate	December 31, 2018 December 31, 2017 Weighted Gross Impairment Gross Impairment % U.S. dollars in thousands U.S. dollars in thousands Not in arrears 1.2 $ 5,464 $ 64 $ 4,502 $ - In arrears up to three months 1.2 1,030 12 1,160 - In arrears up to six months 1.2 221 3 200 35 In arrears up to 12 months 17.5 188 32 71 63 In arrears over 12 months 100.0 159 159 442 442 $ 7,062 $ 270 $ 6,375 $ 540
Schedule of movements in allowance for impairment of receivables	Year Ended December 31, 2018 2017 U.S. dollars in thousands Balance at beginning of year $ 540 $ 450 Recognized impairment loss 104 147 Bad debt (374 ) (57 ) Balance at end of year $ 270 $ 540
Schedule of contractual maturities of financial liabilities	Carrying Contractual Up to 6 6-12 months 1-2 years 2-5 years Over 5 U.S. dollars in thousands December 31, 2018 Non-derivative financial liabilities Short-term bank loans $ 5,000 $ 5,065 $ 5,065 $ - $ - $ - $ - Trade payables 1,517 1,517 1,517 - - - - Other long-term liabilities 1,052 1,052 - - - - 1,052 Other accounts payable 2,767 2,767 2,668 99 - - - Total $ 10,336 $ 10,401 $ 9,250 $ 99 $ - $ - $ 1,052 December 31, 2017 Non-derivative financial liabilities Convertible notes, including current maturities and accrued interest $ 11,022 $ 11,473 $ 11,473 $ - $ - $ - $ - Trade payables 1,262 1,262 1,262 - - - - Other long-term liabilities 948 948 - - - - 948 Other accounts payable 2,714 2,714 2,536 178 - - - Total $ 15,946 $ 16,397 $ 15,271 $ 178 $ - $ - $ 948
Schedule of CPI and foreign currency risk	Currency different from dollar Dollars NIS NIS linked Euro Other Non- Total U.S. dollars in thousands December 31, 2018 Assets Cash and cash equivalents $ 4,088 $ 1,885 $ - $ 426 $ 72 $ - $ 6,471 Trade receivables (including long-term trade receivables) 6,236 229 - 327 - - 6,792 Accounts receivable 247 32 - 2 - 737 1,018 Inventories - - - - - 2,235 2,235 Long-term restricted deposits 109 190 - - - - 299 Long-term prepaid expenses - - - - - 66 66 Property and equipment and intangible assets - - - - - 1,511 1,511 10,680 2,336 - 755 72 4,549 18,392 Liabilities Trade payables 714 798 - 5 - - 1,517 Employee benefits - - - - - 381 381 Provisions - - - - - 215 215 Other accounts payable (including accrued expenses) 1,965 761 - 50 - 321 3,097 Sort-term bank loan 5,000 - - - - - 5,000 Financial derivatives - 442 - - - - 442 Other long-term accounts payable 947 105 - - - - 1,052 8,626 2,106 - 55 - 917 11,704 Total exposure in the statements of financial position in respect of financial assets and financial liabilities $ 2,054 $ 230 $ - $ 700 $ 72 $ 3,632 $ 6,688 December 31, 2017 Assets Cash and cash equivalents $ 2,337 $ 5,124 $ - $ 160 $ 22 $ - $ 7,643 Marketable securities - 1,797 1,376 - - - 3,173 Trade receivables (including long-term trade receivables) 4,952 194 - 689 - - 5,835 Accounts receivable 137 45 - 3 - 500 685 Inventories - - - - - 2,260 2,260 Long-term restricted deposits 108 205 - - - - 313 Long-term prepaid expenses - - - - - 69 69 Property and equipment and intangible assets - - - - - 1,299 1,299 7,534 7,365 1,376 852 22 4,128 21,277 Liabilities Trade payables 382 833 - 47 - - 1262 Employee benefits - - - - - 533 533 Provisions - - - - - 183 183 Other accounts payable (including accrued expenses) 1,877 1,117 - 70 - 339 3,403 Convertible notes - 10,696 - - - - 10,696 Financial derivatives - 2,875 - - - - 2,875 Other long-term accounts payable 905 - 43 - - - 948 3,164 15,521 43 117 - 1,055 19,900 Total exposure in the statements of financial position in respect of financial assets and financial liabilities $ 4,370 $ (8,156 ) $ 1,333 $ 735 $ 22 $ 3,073 $ 1,377
Schedule of sensitivity analysis	December 31, 2018 Equity Profit (loss) U.S. dollars in thousands An increase in the exchange rate of the following currencies against the dollar: NIS/dollar by 5% $ 12 $ 12 Euro/dollar by 5% 35 35 December 31, 2017 Equity Profit (loss) U.S. dollars in thousands An increase in the exchange rate of the following currencies against the dollar: NIS/dollar by 5% $ (340 ) $ (340 ) Euro/dollar by 5% 37 37
Schedule of fair value of other financial assets and liabilities	December 31, 2018 December 31, 2017 Carrying amount Fair value Carrying amount Fair value U.S. dollars in thousands Liabilities: Convertible notes $ - $ - $ **11,118 $ *11,283 Liability in respect of royalties to the IIA and other government institutions 1,151 490 1,072 430 $ 1,151 $ 490 $ 12,190 $ 11,713 * Including interest payable, but excluding the fair value of the embedded warrants. ** Quoted market price on the TASE.
Schedule of financial instruments measured at fair value using valuation method	December 31, 2018 Level 1 Level 3 Total U.S. dollars in thousands Financial instruments - derivative instruments $ - $ 442 $ 442 December 31, 2017 Level 1 Level 3 Total U.S. dollars in thousands Financial instruments - marketable securities $ 3,173 $ - $ 3,173 Financial instruments - derivative instruments - 2,875 2,875

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of transactions between related parties [abstract]
Schedule of compensation	Compensation to key executives includes: Year Ended December 31, 2018 2017 2016 Number Amount Number Amount Number Amount U.S. dollars in U.S. dollars in U.S. dollars in Employee compensation 7 $ 1,835 7 $ 1,384 6 $ 1,590 Share-based payment 7 702 7 1,083 6 1,168 $ 2,537 $ 2,467 $ 2,758 Compensation to directors who are not employed by the Company: Year Ended December 31, 2018 2017 2016 Number of Amount Number of Amount Number of Amount U.S. dollars in U.S. dollars in U.S. dollars in Total benefits to directors not employed by the Company 8 $ 284 9 $ 306 9 $ 278 Year Ended December 31, December 31, 2018 2017 2016 2018 2017 Transaction amounts Carrying amount U.S. dollars in thousands U.S. dollars in thousands Key executives (including directors) of the Company $ 2,821 $ 2,773 $ 3,035 $ 341 $ 1,147

GENERAL (Detail Textuals)

GENERAL (Detail Textuals) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 12, 2019
General Information [Line Items]
Increased credit facility with bank		$ 10
Subsequent Events
General Information [Line Items]
Number of ordinary shares represented by American Depositary Receipts ("ADRs")		30
Increased credit facility with bank			$ 15
Subsequent Events | 2018 Private Placement
General Information [Line Items]
Total consideration raised	$ 14.7

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2018
Office furniture and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates, property, plant and equipment	10%
Equipment and devices for leasing and for internal use
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates, property, plant and equipment	15%
Computers
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates, property, plant and equipment	33%

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
Disclosure Of Significant Accounting Policies [Line Items]
Increasing balance of right-of-use assets	$ 1.1
Additional lease period of Israel offices	30 months
Increase balance of right of use assets	$ 0.8
Dollar-denominated leases
Disclosure Of Significant Accounting Policies [Line Items]
Nominal discount rates used for measuring lease liabilities	5.30%
NIS-denominated leases | Bottom of range
Disclosure Of Significant Accounting Policies [Line Items]
Nominal discount rates used for measuring lease liabilities	8.50%
NIS-denominated leases | Top of range
Disclosure Of Significant Accounting Policies [Line Items]
Nominal discount rates used for measuring lease liabilities	8.90%

TRADE AND OTHER RECEIVABLES (De

TRADE AND OTHER RECEIVABLES (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Trade receivables:
Open accounts	$ 7,040	$ 6,048
Checks receivable	22	327
Trade receivable gross	7,062	6,375
Less - allowance for doubtful accounts	270	540
Trade receivables	6,792	5,835
Is presented in the statements of financial position as follows:
Under current assets	6,549	5,362
Under non-current assets	243	473
Trade receivable	$ 6,792	$ 5,835

TRADE AND OTHER RECEIVABLES (_2

TRADE AND OTHER RECEIVABLES (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other receivables:
Institutions	$ 181	$ 330
Advances to suppliers	187	51
Employees	91	121
Prepaid expenses	556	170
Miscellaneous	3	13
Other receivables	$ 1,018	$ 685

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Classes of current inventories [abstract]
Raw materials and auxiliary materials	$ 1,158	$ 969
Work in process	277	214
Finished products	800	1,077
Inventory, Total	$ 2,235	$ 2,260

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [line items]
Balance	$ 1,022
Balance	1,213	$ 1,022
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	3,824	3,409
Additions	514	438
Disposals		(23)
Balance	4,338	3,824
Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	2,802	2,401
Depreciation	323	410
Disposals		(9)
Balance	3,125	2,802
Computers and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Balance	315
Balance	314	315
Computers and equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	1,947	1,883
Additions	62	64
Disposals		0
Balance	2,009	1,947
Computers and equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	1,632	1,570
Depreciation	63	62
Disposals		0
Balance	1,695	1,632
Equipment and devices for leasing and for internal use
Disclosure of detailed information about property, plant and equipment [line items]
Balance	444
Balance	673	444
Equipment and devices for leasing and for internal use | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	1,093	750
Additions	434	349
Disposals		(6)
Balance	1,527	1,093
Equipment and devices for leasing and for internal use | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	649	409
Depreciation	205	240
Disposals		0
Balance	854	649
Office furniture and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Balance	148
Balance	131	148
Office furniture and equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	467	459
Additions	9	21
Disposals		(13)
Balance	476	467
Office furniture and equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	319	255
Depreciation	26	71
Disposals		(7)
Balance	345	319
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Balance	115
Balance	95	115
Leasehold improvements | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	317	317
Additions	9	4
Disposals		(4)
Balance	326	317
Leasehold improvements | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	202	167
Depreciation	29	37
Disposals		(2)
Balance	$ 231	$ 202

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [abstract]
original cost of assets	$ 2,928	$ 2,614

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about intangible assets [line items]
Balance	$ 277
Balance	298	$ 277
Cost
Disclosure of detailed information about intangible assets [line items]
Balance	1,837	1,685
Additions	113	152
Balance	1,950	1,837
Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Balance	1,560	1,428
Amortization for the year	92	132
Balance	1,652	1,560
Computer software
Disclosure of detailed information about intangible assets [line items]
Balance	68
Balance	53	68
Computer software | Cost
Disclosure of detailed information about intangible assets [line items]
Balance	746	704
Additions	23	42
Balance	769	746
Computer software | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Balance	678	602
Amortization for the year	38	76
Balance	716	678
Capitalized development cost
Disclosure of detailed information about intangible assets [line items]
Balance	209
Balance	245	209
Capitalized development cost | Cost
Disclosure of detailed information about intangible assets [line items]
Balance	716	606
Additions	90	110
Balance	806	716
Capitalized development cost | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Balance	507	471
Amortization for the year	54	36
Balance	561	507
Marketing rights for a medical product
Disclosure of detailed information about intangible assets [line items]
Balance	0
Balance	0	0
Marketing rights for a medical product | Cost
Disclosure of detailed information about intangible assets [line items]
Balance	375	375
Additions	0	0
Balance	375	375
Marketing rights for a medical product | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Balance	375	355
Amortization for the year	0	20
Balance	$ 375	$ 375

EMPLOYEE BENEFITS (Details)

EMPLOYEE BENEFITS (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Presented as part of current liabilities - accounts payable:
Short-term employee benefits	$ 222	$ 223
Presented as part of non-current liabilities:
Long-term employee benefits	$ 159	$ 310

EMPLOYEE BENEFITS (Details 1)

EMPLOYEE BENEFITS (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of information about defined benefit plans [abstract]
Balance at beginning of year	$ 310	$ 156
Expense recognized in the statements of operations:
Current service costs and interest costs	29	61
Recognized loss including other:
Actuarial losses carried to other comprehensive income	(166)	112
Other movements:
Benefits paid	(5)	0
Deposits made by the Group	(9)	(19)
Balance at end of year	$ 159	$ 310

EMPLOYEE BENEFITS (Details 2)

EMPLOYEE BENEFITS (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of information about defined benefit plans [abstract]
Current service costs	$ 16	$ 21
Interest costs	7	6
Transfer of profits to benefits	28	18
Total	$ 51	$ 45

EMPLOYEE BENEFITS (Details 3)

EMPLOYEE BENEFITS (Details 3)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of information about defined benefit plans [abstract]
Discount rate at the end of the year	3.82%	2.74%	3.35%
Future salary growth	3.00%	3.27%	3.32%

CREDIT FACILITY WITH A BANK A_2

CREDIT FACILITY WITH A BANK AND CONVERTIBLE NOTES (Details) ₪ / shares in Units, $ / shares in Units, ₪ in Thousands

Mar. 12, 2019USD ($)$ / sharesshares

Mar. 12, 2019USD ($)₪ / sharesshares

Feb. 21, 2019USD ($)

Jun. 30, 2018USD ($)

Jan. 30, 2018

Mar. 31, 2017USD ($)

Mar. 31, 2013USD ($)$ / shares

Mar. 31, 2013ILS (₪)₪ / shares

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2018USD ($)₪ / sharesshares

Feb. 28, 2018USD ($)

Feb. 28, 2018ILS (₪)

Feb. 28, 2017USD ($)

Feb. 28, 2017ILS (₪)

Debt Instruments [Line Items]

Long term line of credit

$ 10,000,000

Long-term loan

6,000,000

Credit facility against trade accounts receivable

$ 4,000,000

Percentage of line of credit facility average outstanding

40.00%

Number of warrants exercisable | shares

798,088

798,088

Warrant exercise price | (per share)

$ 0.36

₪ 1.36

Fair value adjustment of warrant

$ 137,000

Increased credit facility with bank

10,000,000

₪ 10,000,000

Short term line of credit

5,000,000

5,000,000

Short Term Borrowing

2,250,000

2,250,000

Short-term loan against trade accounts receivable

$ 2,750,000

₪ 2,750,000

Issue of par value of convertible notes | ₪

₪ 72,256

Proceeds of convertible debt

$ 19,500,000

Percentage of long term debt and capital lease obligations including current maturities

8.65%

Debt instrument interest rate effective, percentage

27.70%

Debt conversion into ordinary share | (per share)

$ 1.00904

₪ 1.92

Amount of convertible debt

$ 10,940,000

₪ 38,128

$ 10,421,000

₪ 38,128

Repayment of convertible debt

$ 500,000

Three shareholders

Debt Instruments [Line Items]

Amount of convertible debt

$ 1,700

₪ 6,000

Subsequent Events

Debt Instruments [Line Items]

Credit facility against trade accounts receivable

$ 6,000,000

$ 6,000,000

Number of warrants exercisable | shares

399,044

399,044

Warrant exercise price | (per share)

$ 0.36

$ 1.30

Fair value adjustment of warrant

$ 62,000

Increased credit facility with bank

15,000,000

$ 15,000,000

Long term or short term debt

$ 9,000,000

$ 9,000,000

Short term line of credit

$ 5,000,000

Short Term Borrowing

2,050,000

Short-term loan against trade accounts receivable

$ 2,950,000

Percentage of line of credit facility outstanding commitment

40.00%

Line of credit facility amount outstanding

$ 2,000,000

LIBOR rate

Debt Instruments [Line Items]

Description of line of credit facility interest rate

quarterly dollar LIBOR rate plus 5.5%. The credit facility bears annual interest of the monthly dollar LIBOR rate plus 4.25%.

PROVISIONS (Details)

PROVISIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of other provisions [line items]
Balance	$ 183	$ 167
Provisions made during the year	167	226
Provisions reversed during the year	(5)	(27)
Provisions realized during the year	(130)	(183)
Balance	215	183
Warranties
Disclosure of other provisions [line items]
Balance	100	93
Provisions made during the year	86	135
Provisions reversed during the year	(5)	(27)
Provisions realized during the year	(62)	(101)
Balance	119	100
Returns
Disclosure of other provisions [line items]
Balance	83	74
Provisions made during the year	81	91
Provisions reversed during the year	0	0
Provisions realized during the year	(68)	(82)
Balance	$ 96	$ 83

OTHER ACCOUNTS PAYABLE (Details

OTHER ACCOUNTS PAYABLE (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Trade and other payables [abstract]
Employees	$ 1,403	$ 1,117
Institutions	319	339
Interest payable	11	326
Deferred revenues and advances from customers	255	193
Other	75	23
Other accounts payable	$ 2,063	$ 1,998

DERIVATIVES (Details)

DERIVATIVES (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Liabilities
The conversion component in the convertible notes		$ 0	$ 96
Viola Warrants (non-traded)	[1]	371	2,315
Warrants (Series 4) (traded) issued in the 2015 rights offering	[1]	71	464
Liabilities		$ 442	$ 2,875
[1]	See Note 14c.

DERIVATIVES (Details 1)

DERIVATIVES (Details 1) - ₪ / shares	Dec. 31, 2018	Dec. 31, 2017
Derivative Instrument [Abstract]
Discount rate for notes which were fully repaid on February 28, 2018 (yield to maturity of the notes)	0.00%	104.18%
The discount rate of the Viola Warrants and Warrants (Series 4) (risk free interest)	0.30%	0.11%
Share price (in NIS)	₪ 1.280	₪ 1.340
Standard deviation of the share price	54.59%	56.13%

COMMITMENTS (Details)

COMMITMENTS (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019
Disclosure Of Commitments [Line Items]
Minimum lease commitments expected under these operating leases	$ 847
2020
Disclosure Of Commitments [Line Items]
Minimum lease commitments expected under these operating leases	720
2021
Disclosure Of Commitments [Line Items]
Minimum lease commitments expected under these operating leases	452
2022
Disclosure Of Commitments [Line Items]
Minimum lease commitments expected under these operating leases	$ 54

COMMITMENTS (Detail Textuals)

COMMITMENTS (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
2019
Disclosure of finance lease and operating lease by lessee [line items]
Minimum lease payments under non-cancelable lease agreements	$ 319
2020
Disclosure of finance lease and operating lease by lessee [line items]
Minimum lease payments under non-cancelable lease agreements	333
2021
Disclosure of finance lease and operating lease by lessee [line items]
Minimum lease payments under non-cancelable lease agreements	181
Israeli Government's Innovation Authority ("IIA")
Disclosure of finance lease and operating lease by lessee [line items]
Payment of royalties	$ 1,046

INCOME TAXES (Detail Textuals)

INCOME TAXES (Detail Textuals) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of geographical areas [line items]
Percentage of minimum threshold of export sales	25.00%
Accumulated carryforward tax losses (including carryforward research and development expenses)	$ 111
U.S. - federal tax rate	21.00%	35.00%	35.00%
Israeli
Disclosure of geographical areas [line items]
Percentages of tax rates relevant to corporates	23.00%	24.00%	25.00%
Netherlands
Disclosure of geographical areas [line items]
Percentages of tax rates relevant to corporates	20.00%	20.00%
Japan
Disclosure of geographical areas [line items]
Percentages of tax rates relevant to corporates	23.20%	23.40%	23.40%

EQUITY (Details)

EQUITY (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Issued and outstanding share capital (ordinary shares):
Outstanding shares at the beginning of the year	264,495	262,917	259,581
Shares issued in private placements during the year	22,014	0	2,976
Shares issued in exercise of stock options during the year	1,107	1,578	360
Outstanding at the end of the year	287,616	264,495	262,917
Authorized	750,000	750,000	750,000

EQUITY (Detail Textuals)

EQUITY (Detail Textuals) ₪ / shares in Units, $ / shares in Units, $ in Thousands, ₪ in Millions	May 07, 2018$ / shares	Nov. 05, 2015USD ($)$ / sharesshares	Nov. 05, 2015ILS (₪)₪ / sharesshares	May 27, 2018USD ($)shares	May 27, 2018ILS (₪)₪ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015ILS (₪)₪ / sharesshares	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2016USD ($)
Equity [Line Items]
Proceeds from issuing shares | $								$ 5,209	$ 998
Securities purchase agreement | 2018 Private Placement
Equity [Line Items]
Share issued price per share | ₪ / shares					₪ 0.947
Number of consecutive trading days				15 days	15 days
Proceeds from issuing shares				$ 6,000	₪ 20.8
Securities purchase agreement | Viola
Equity [Line Items]
Number of ordinary shares issued		66,876,907	66,876,907
Share issued price per share | (per share)		$ 0.38	₪ 1.449
Proceeds from issuing shares		$ 25,200	₪ 96.9
Number of warrants exercisable into ordinary shares		33,438,454	33,438,454
Pre-money valuation for warrants at expiry in event of public offering | $		$ 250,000
Maximum value for warrants at expiry in event of merger or sale | $		$ 250,000
Securities purchase agreement | Viola | Exercise price for first 21 months following issuance of warrants
Equity [Line Items]
Exercise price of warrants | (per share)			₪ 1.642					$ 0.44
Securities purchase agreement | Viola | Exercise price for remainder of term
Equity [Line Items]
Exercise price of warrants | (per share)			₪ 1.745					0.47
Securities purchase agreement | Viola | 2018 Private Placement
Equity [Line Items]
Number of ordinary shares issued				22,013,893	22,013,893
Percentage of issued and outstanding shares on post issuance basis				7.70%	7.70%
Share issued price per share | $ / shares	$ 0.27
Percentage of discount on average share price				7.00%	7.00%
Proceeds from issuing shares | ₪					₪ 5.2
Securities purchase agreement | Other shareholders | Rights offering
Equity [Line Items]
Number of ordinary shares issued						12,876,303	12,876,303
Share issued price per share | (per share)						$ 0.37	₪ 1.449
Proceeds from issuing shares						$ 4,700	₪ 18.7
Number of warrants exercisable into ordinary shares						6,438,152	6,438,152
Securities purchase agreement | Other shareholders | Rights offering | Exercise price for first 21 months following issuance of warrants
Equity [Line Items]
Exercise price of warrants | (per share)							₪ 1.642	0.44
Securities purchase agreement | Other shareholders | Rights offering | Exercise price for remainder of term
Equity [Line Items]
Exercise price of warrants | (per share)							₪ 1.745	$ 0.47
Securities purchase agreement | Medtronic | 2018 Private Placement
Equity [Line Items]
Proceeds from issuing shares | ₪					2.4
Securities purchase agreement | Dr. Giora Yaron | 2018 Private Placement
Equity [Line Items]
Proceeds from issuing shares | ₪					₪ 2.1

SHARE-BASED PAYMENTS (Details)

SHARE-BASED PAYMENTS (Details) - Employees, directors and consultants shares in Thousands	12 Months Ended
	Dec. 31, 2018ILS (₪)Yearsshares
Options with service conditions only
Disclosure of terms and conditions of share-based payment arrangement [line items]
The number of shares arising from the exercise of the options (in thousands) | shares	1,313
The parameters included when calculating fair value:
Expected dividend rate	0.00%
Options with service conditions only | Bottom of range
The parameters included when calculating fair value:
The share price (at the grant date) (in NIS)	₪ 1.10
Exercise price, share options granted	₪ 1.12
Expected volatility (weighted average)	55.00%
Expected lifetime (weighted average) | Years	3.5
Risk-free interest rate	0.91%
Options with service conditions only | Top of range
The parameters included when calculating fair value:
The share price (at the grant date) (in NIS)	₪ 1.25
Exercise price, share options granted	₪ 1.29
Expected volatility (weighted average)	58.00%
Expected lifetime (weighted average) | Years	4
Risk-free interest rate	1.13%
Options with service conditions and market conditions
Disclosure of terms and conditions of share-based payment arrangement [line items]
The number of shares arising from the exercise of the options (in thousands) | shares	1,283
The parameters included when calculating fair value:
Expected dividend rate	0.00%
Options with service conditions and market conditions | Bottom of range
The parameters included when calculating fair value:
The share price (at the grant date) (in NIS)	₪ 1.10
Exercise price, share options granted	₪ 1.02
Expected volatility (weighted average)	55.00%
Expected lifetime (weighted average) | Years	4.7
Risk-free interest rate	1.27%
Options with service conditions and market conditions | Top of range
The parameters included when calculating fair value:
The share price (at the grant date) (in NIS)	₪ 1.25
Exercise price, share options granted	₪ 1.17
Expected volatility (weighted average)	56.00%
Expected lifetime (weighted average) | Years	5
Risk-free interest rate	1.46%
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
The number of shares arising from the exercise of the options (in thousands) | shares	296
The parameters included when calculating fair value:
Expected lifetime (weighted average) | Years	0
Expected dividend rate	0.00%
RSUs | Bottom of range
The parameters included when calculating fair value:
The share price (at the grant date) (in NIS)	₪ 1.10
Exercise price, share options granted	₪ 0
Expected volatility (weighted average)	55.00%
RSUs | Top of range
The parameters included when calculating fair value:
The share price (at the grant date) (in NIS)	₪ 1.25
Exercise price, share options granted	₪ 0.30
Expected volatility (weighted average)	56.00%

SHARE-BASED PAYMENTS (Details 1

SHARE-BASED PAYMENTS (Details 1) - CEO and to officers and key employees	12 Months Ended
	Dec. 31, 2018Years
Service options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	57.60%
Expected dividends rate	0.00%
Service options | Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Average lifetime (in years)	4.8
Risk free interest rate	0.91%
Service options | Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Average lifetime (in years)	5.9
Risk free interest rate	1.36%
Performance options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	57.60%
Average lifetime (in years)	8.8
Risk free interest rate	2.00%
Expected dividends rate	0.00%

SHARE-BASED PAYMENTS (Details 2

SHARE-BASED PAYMENTS (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number Of Share Options And Other Than Option Outstanding In Share-Based Payment Arrangement [Roll Forward]
Outstanding at beginning of year	35,892,484	40,178,148	24,316,648
Granted during the year	3,312,056	4,105,076	28,180,067
Forfeited and expired during the year	(2,305,527)	(6,825,690)	(11,962,761)
Exercised during the year	(1,096,800)	(1,565,050)	(355,806)
Outstanding at end of year	35,802,213	35,892,484	40,178,148
Exercisable at end of year	10,114,392	9,716,559	12,319,881
Exercise Price Of Outstanding Share Options And Other Than Option [Roll Forward]
Forfeited and expired range of exercise price during the year	$ 0	$ 0	$ 0
Exercised range of exercise price during the year		0.23
Bottom of range
Exercise Price Of Outstanding Share Options And Other Than Option [Roll Forward]
Outstanding range of exercise price at beginning of year	0	0	0.10
Granted range of exercise price during the year	0	0	0
Exercised range of exercise price during the year	0.23		0.10
Outstanding range of exercise price at end of year	0	0	0
Exercisable range of exercise price at end of year	0.23	0.23	0.23
Top of range
Exercise Price Of Outstanding Share Options And Other Than Option [Roll Forward]
Outstanding range of exercise price at beginning of year	2.50	2.50	2.50
Granted range of exercise price during the year	1.29	1.68	1.55
Exercised range of exercise price during the year	0.51		0.48
Outstanding range of exercise price at end of year	2.50	2.50	2.50
Exercisable range of exercise price at end of year	$ 2.50	$ 2.50	$ 2.50
Options with service conditions only
Number Of Share Options And Other Than Option Outstanding In Share-Based Payment Arrangement [Roll Forward]
Outstanding at end of year	15,661,344
Options with service conditions and market conditions
Number Of Share Options And Other Than Option Outstanding In Share-Based Payment Arrangement [Roll Forward]
Outstanding at end of year	16,699,449
RSUs
Number Of Share Options And Other Than Option Outstanding In Share-Based Payment Arrangement [Roll Forward]
Outstanding at end of year	3,441,420

SHARE-BASED PAYMENTS (Details 3

SHARE-BASED PAYMENTS (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Share Based Payments [Abstract]
Cost of revenues	$ 10	$ 9	$ 30
Selling and marketing expenses	295	336	429
Research and development expenses	104	87	257
General and administrative expense	612	740	1,060
Financial expenses from notes and loans	0	122	0
Total share-based compensation expenses	$ 1,021	$ 1,294	$ 1,776

SHARE-BASED PAYMENTS (Detail Te

SHARE-BASED PAYMENTS (Detail Textuals) $ / shares in Units, $ in Thousands	Mar. 14, 2018₪ / shares	Jan. 21, 2016₪ / shares	Dec. 31, 2018USD ($)$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Period of vest under share-based plan for options and RSUs for key employees	Jan. 21, 2020		Dec. 22, 2020
Lowest share price per share under merger and acceleration event | (per share)		₪ 2.13	$ 0.57
Percentage of issued and outstanding share capital under merger			10.00%
Weighted average fair value at measurement date, share options granted			$ 475
Description of shares option		On January 21, 2016, the Company’s Board of Directors, as part of the share-based plan described in (2) above, also approved a grant of options that will vest as followed: 25% will vest and become exercisable one year following the date of grant and the remaining 75% will vest and become exercisable in 12 equal quarterly portions, beginning on the first anniversary of the date of grant.
Other employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of shares option		Grants to other employees not participating in the key employees share-based plan, usually vest over four years, as follows: 2/3 will vest and be exercisable two years following the date of grant, and the remaining 1/3 will vest and become exercisable in four equal quarterly portions, at the end of each calendar quarter commencing on the second anniversary of the date of grant.
Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of shares option		Options granted to directors during the years ended December 31, 2016, 2017 and 2018, were usually divided into three tranches, each equal to 33% of the amount of options granted. The allotment and the vesting period for the first tranche began on the date of grant; the allotment and the vesting period for the second tranche will begin on first anniversary of the date of grant; and the allotment and the vesting period for the third tranche will begin on the third anniversary of the date grant. Each tranche vests in four equal portions annually over four years.
Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
First Trigger Price | (per share)	₪ 1.70		$ 0.45
Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
First Trigger Price | (per share)	₪ 2.13		$ 0.57
New share-based plan for options and RSUs for key employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date, share options granted			$ 239
New share-based plan for options and RSUs for key employees | 50% of RSUs vest
Disclosure of terms and conditions of share-based payment arrangement [line items]
Period of vest under share-based plan for options and RSUs for key employees		Jan. 21, 2020
Percentage of vesting		50.00%
First Trigger Price | (per share)		₪ 2.13	$ 0.57
New share-based plan for options and RSUs for key employees | 100% RSUs vest
Disclosure of terms and conditions of share-based payment arrangement [line items]
Period of vest under share-based plan for options and RSUs for key employees		Jan. 21, 2020
Percentage of vesting		100.00%
First Trigger Price | (per share)		₪ 4.24	$ 1.13

SHARE-BASED PAYMENTS (Detail _2

SHARE-BASED PAYMENTS (Detail Textuals 1)	Mar. 21, 2017share	Jan. 30, 2019share$ / sharesshares	Jan. 30, 2019share₪ / sharesshares	Aug. 31, 2018shareEmployee	Mar. 31, 2018shareEmployee	Sep. 30, 2017shareEmployee	May 31, 2017share	Feb. 28, 2017shareEmployee	Sep. 30, 2016share	May 31, 2016share	Mar. 31, 2016share	Dec. 31, 2015share	Dec. 31, 2014share	Dec. 31, 2018person	Dec. 31, 2017person	Dec. 31, 2016person
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of persons employee compensation | person														8	9	9
Number of shares options granted	18,890,695
January 2016 plan under options and RSUs | Subsequent Events
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options exercisable in share-based payment arrangement		1,968,954	1,968,954
Number of performance-based RSUs granted to employees | shares		339,495	339,495
January 2016 plan under options and RSUs | Subsequent Events | Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Period of expire under stock options		2024	2024
Ordinary shares at exercise price | (per share)		$ 0.35	₪ 1.30
January 2016 plan under options and RSUs | Subsequent Events | Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Period of expire under stock options		2026	2026
Ordinary shares at exercise price | (per share)		$ 0.39	₪ 1.43
January 2016 plan under options and RSUs | Other employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of persons employee compensation | Employee				12		11		15
Number of shares options granted				530,137		2,281,218		711,000	1,114,129		3,755,847	741,314	741,314
Number of RSUs granted				17,160		362,858			72,545
January 2016 plan under options and RSUs | CEO
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares options granted											3,620,834
January 2016 plan under options and RSUs | Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares options granted							440,000			1,759,999
January 2016 plan under options and RSUs | Employees And Officers
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of persons employee compensation | Employee					20
Number of shares options granted					1,802,512
Number of RSUs granted					229,534
January 2016 plan under options and RSUs | Consultant
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares options granted					263,681	100,000	100,000
Number of RSUs granted					49,032
January 2016 plan under options and RSUs | Employees officers and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares options granted											15,270,957
Number of RSUs granted											3,465,761

SHARE-BASED PAYMENTS (Detail _3

SHARE-BASED PAYMENTS (Detail Textuals 2)	Mar. 21, 2017share	Dec. 31, 2018USD ($)Years	Dec. 31, 2017USD ($)Years	Dec. 31, 2016USD ($)Years
Disclosure of terms and conditions of share-based payment arrangement [line items]
Non-cash expense of grant options and RSU		$ 1,021,000	$ 1,294,000	$ 1,776,000
Balance expenditure of remaining vesting period options and RSUs		1,090,000
Weighted average share price upon exercise of options		$ 0.35	$ 0.35	$ 0.34
Weighted average remaining contractual life of options outstanding | Years		5.74	6.23	4.22
Number of instruments granted in share-based payment arrangement | share	18,890,695
Weighted average fair value at measurement date, share options granted		$ 475,000
Service options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments granted in share-based payment arrangement | share	3,699,208
Service and market conditions to officers and key employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments granted in share-based payment arrangement | share	15,191,487

REVENUES (Details)

REVENUES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Breakdown Of Revenues On The Basis Product Groups [Line Items]
Revenues	$ 24,189	$ 20,701	$ 18,440
WatchPAT and other related services
Disclosure Of Breakdown Of Revenues On The Basis Product Groups [Line Items]
Revenues	22,384	18,105	15,697
Endo PAT and other related services
Disclosure Of Breakdown Of Revenues On The Basis Product Groups [Line Items]
Revenues	$ 1,805	$ 2,596	$ 2,743

REVENUES (Details 1)

REVENUES (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	$ 24,189	$ 20,701	$ 18,440
United States and Canada
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	17,582	14,764	13,343
Japan
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	3,374	2,965	2,161
Europe
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	1,885	1,746	1,542
Asia Pacific (including Japan)
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	849	759	1,017
Israel
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	281	260	268
Others
Disclosure Of Revenues On The Basis Of Geographical Region [Line Items]
Revenue	$ 218	$ 207	$ 109

REVENUES (Details 2)

REVENUES (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of major customers [line items]
Revenue	$ 10,670	$ 8,753	$ 7,764
Customer A
Disclosure of major customers [line items]
Revenue	4,571	3,622	3,549
Customer B
Disclosure of major customers [line items]
Revenue	3,229	2,621	2,119
Customer C
Disclosure of major customers [line items]
Revenue	$ 2,870	$ 2,510	$ 2,096

COST OF REVENUES (Details)

COST OF REVENUES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Cost Of Sales [Abstract]
Raw materials, auxiliary materials, subcontractors (including changes in inventories)	$ 2,538	$ 1,767	$ 2,173
Payroll and related expenses (including share-based payment)	1,806	1,956	1,749
Shipping	443	500	386
Depreciation and amortization	255	190	124
Other	684	589	547
Cost of revenues	$ 5,726	$ 5,002	$ 4,979

FINANCIAL INCOME AND EXPENSES_2

FINANCIAL INCOME AND EXPENSES (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Financial income from cash and investments:
In respect of investments in bank deposits and marketable securities	[1]	$ 93	$ 1,389	$ 547
Other financial income		151	202	169
Financial income from cash and investments		244	1,591	716
Financial expenses from notes, loans and other:
Convertible notes	[1]	393	4,427	4,610
Short-term bank loan		316	0	0
Short-term shareholders' loans		85	0	0
Other financial expenses		359	427	185
Exchange rate differences		8	30	(35)
Financial expenses from notes, loans and other		1,161	4,884	4,760
Gain (loss) on derivative financial instruments:
Gain on revaluation to fair value of the warrants embedded in the convertible notes		96	2,141	1,567
Gain (loss) on revaluation to fair value of warrants		2,337	1,784	(1,783)
Gain (loss) on derivative financial instruments		$ 2,433	$ 3,925	$ (216)
[1]	Including the effect of changes in the exchange rate of the NIS against the dollar.

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings per share [abstract]
Net loss attributed to the ordinary shares	$ (1,729)	$ (5,301)	$ (14,403)

LOSS PER SHARE (Details 1)

LOSS PER SHARE (Details 1) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings per share [abstract]
Balance at the beginning of the year	264,495	262,917	259,581
The effect of private placement and rights offering	12,908	0	2,716
The effect of exercise of options into shares	262	1,192	245
Weighted average number of ordinary shares used in computation of basic loss per share	277,665	264,109	262,542

LOSS PER SHARE (Details 2)

LOSS PER SHARE (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings per share [abstract]
Net loss used in computation of basic earnings per share	$ (1,729)	$ (5,301)	$ (14,403)
Changes in the fair value of the Viola warrants and Warrants (Series 4), which are classified as a liability	(2,434)	(1,785)	0
Net loss attributed to the ordinary shares (diluted)	$ (4,163)	$ (7,086)	$ (14,403)

LOSS PER SHARE (Details 3)

LOSS PER SHARE (Details 3) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings per share [abstract]
Weighted average number of ordinary shares used in computation of basic loss per share	277,665	264,109	262,542
Effect of the exercise of the Viola warrants and Warrants (Series 4)	43,246	39,877	0
Weighted average number of ordinary shares used in computation of diluted loss per share per share	320,911	303,986	262,542

LOSS PER SHARE (Detail Textuals

LOSS PER SHARE (Detail Textuals) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Convertible note
Antidilutive Securities [Line Items]
Antidilutive securities computation of earnings per share amount	3,369,797	23,588,582	40,075,289
Warrant
Antidilutive Securities [Line Items]
Antidilutive securities computation of earnings per share amount	33,438,454		33,438,454
Options
Antidilutive Securities [Line Items]
Antidilutive securities computation of earnings per share amount	32,412,199	32,719,056	36,779,259
RSUs
Antidilutive Securities [Line Items]
Antidilutive securities computation of earnings per share amount	3,441,420	3,242,632	3,398,889
Warrants Series 4
Antidilutive Securities [Line Items]
Antidilutive securities computation of earnings per share amount			6,438,152

FINANCIAL INSTRUMENTS (Details)

FINANCIAL INSTRUMENTS (Details) $ in Thousands	Dec. 31, 2017USD ($)
Disclosure of detailed information about financial instruments [line items]
Investments in marketable securities	$ 3,173
Government bonds - NIS linked to the Israeli CPI
Disclosure of detailed information about financial instruments [line items]
Investments in marketable securities	368
Government bonds - NIS
Disclosure of detailed information about financial instruments [line items]
Investments in marketable securities	838
Corporate bonds - NIS linked to the Israeli CPI
Disclosure of detailed information about financial instruments [line items]
Investments in marketable securities	1,008
Corporate bonds - NIS
Disclosure of detailed information about financial instruments [line items]
Investments in marketable securities	777
Current account
Disclosure of detailed information about financial instruments [line items]
Investments in marketable securities	$ 182

FINANCIAL INSTRUMENTS (Details

FINANCIAL INSTRUMENTS (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investment	$ 13,843	$ 17,149
Israel
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investment	5,378	9,581
United States and Canada
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investment	6,337	5,815
Asia Pacific (including Japan)
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investment	936	817
Europe
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investment	998	909
Other
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk in respect of cash and cash and cash equivalents, trade receivables, other accounts receivable and other investment	$ 194	$ 27

FINANCIAL INSTRUMENTS (Detail_2

FINANCIAL INSTRUMENTS (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [line items]
Gross amount	$ 7,062	$ 6,375
Impairment	$ 270	540	$ 450
Not in arrears
Disclosure of detailed information about financial instruments [line items]
Weighted average loss rate	1.20%
Gross amount	$ 5,464	4,502
Impairment	$ 64	0
In arrears up to three months
Disclosure of detailed information about financial instruments [line items]
Weighted average loss rate	1.20%
Gross amount	$ 1,030	1,160
Impairment	$ 12	0
In arrears up to six months
Disclosure of detailed information about financial instruments [line items]
Weighted average loss rate	1.20%
Gross amount	$ 221	200
Impairment	$ 3	35
In arrears up to 12 months
Disclosure of detailed information about financial instruments [line items]
Weighted average loss rate	17.50%
Gross amount	$ 188	71
Impairment	$ 32	63
In arrears over 12 months
Disclosure of detailed information about financial instruments [line items]
Weighted average loss rate	100.00%
Gross amount	$ 159	442
Impairment	$ 159	$ 442

FINANCIAL INSTRUMENTS (Detail_3

FINANCIAL INSTRUMENTS (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Balance at beginning of year	$ 540	$ 450
Recognized impairment loss	104	147
Bad debt	(374)	(57)
Balance at end of year	$ 270	$ 540

FINANCIAL INSTRUMENTS (Detail_4

FINANCIAL INSTRUMENTS (Details 4) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Non-derivative financial liabilities
Short-term bank loan	$ 5,000
Convertible notes, including current maturities and accrued interest		$ 11,022
Trade payables	1,517	1,262
Other long-term liabilities	1,052	948
Other accounts payable	2,767	2,714
Total	10,336	15,946
Contractual Cash flow
Short-term bank loans	5,065
Convertible notes, including current maturities and accrued interest		11,473
Trade payables	1,517	1,262
Other long-term liabilities	1,052	948
Other accounts payable	2,767	2,714
Total	10,401	16,397
Up to 6 months
Non-derivative financial liabilities
Short-term bank loan	5,065
Convertible notes, including current maturities and accrued interest		11,473
Trade payables	1,517	1,262
Other long-term liabilities	0	0
Other accounts payable	2,668	2,536
Total	9,250	15,271
6-12 months
Non-derivative financial liabilities
Short-term bank loan	0
Convertible notes, including current maturities and accrued interest		0
Trade payables	0	0
Other long-term liabilities	0	0
Other accounts payable	99	178
Total	99	178
1-2 years
Non-derivative financial liabilities
Short-term bank loan	0
Convertible notes, including current maturities and accrued interest		0
Trade payables	0	0
Other long-term liabilities	0	0
Other accounts payable	0	0
Total	0	0
2-5 years
Non-derivative financial liabilities
Short-term bank loan	0
Convertible notes, including current maturities and accrued interest		0
Trade payables	0	0
Other long-term liabilities	0	0
Other accounts payable	0	0
Total	0	0
Over 5 years
Non-derivative financial liabilities
Short-term bank loan	0
Convertible notes, including current maturities and accrued interest		0
Trade payables	0	0
Other long-term liabilities	1,052	948
Other accounts payable	0	0
Total	$ 1,052	$ 948

FINANCIAL INSTRUMENTS (Detail_5

FINANCIAL INSTRUMENTS (Details 5) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 6,471	$ 7,643	$ 23,358	$ 33,019
Marketable securities		3,173
Trade receivables (including long-term trade receivables)	6,792	5,835
Accounts receivable	1,018	685
Inventories	2,235	2,260
Long-term restricted deposits	299	313
Long-term prepaid expenses	66	69
Property and equipment and intangible assets	1,511	1,299
Total assets	18,392	21,277
Liabilities
Trade payables	1,517	1,262
Employee benefits	222	533
Provisions	215	183	167
Other accounts payable (including accrued expenses)	3,097	3,403
Short-term bank loan	5,000
Financial derivatives	442	2,875
Other long-term accounts payable	1,052	948
Total liabilities	11,704	19,900
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	6,688	1,377	$ 5,241	$ 16,951
Currency risk | Dollars
Assets
Cash and cash equivalents	4,088	2,337
Marketable securities		0
Trade receivables (including long-term trade receivables)	6,236	4,952
Accounts receivable	247	137
Inventories	0	0
Long-term restricted deposits	109	108
Long-term prepaid expenses	0	0
Property and equipment and intangible assets	0	0
Total assets	10,680	7,534
Liabilities
Trade payables	714	382
Employee benefits	0	0
Provisions	0	0
Other accounts payable (including accrued expenses)	1,965	1,877
Short-term bank loan	5,000	0
Financial derivatives	0	0
Other long-term accounts payable	947	905
Total liabilities	8,626	3,164
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	2,054	4,370
Currency risk | NIS
Assets
Cash and cash equivalents	1,885	5,124
Marketable securities		1,797
Trade receivables (including long-term trade receivables)	229	194
Accounts receivable	32	45
Inventories	0	0
Long-term restricted deposits	190	205
Long-term prepaid expenses	0	0
Property and equipment and intangible assets	0	0
Total assets	2,336	7,365
Liabilities
Trade payables	798	833
Employee benefits	0	0
Provisions	0	0
Other accounts payable (including accrued expenses)	761	1,117
Short-term bank loan	0	10,696
Financial derivatives	442	2,875
Other long-term accounts payable	105	0
Total liabilities	2,106	15,521
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	230	(8,156)
Currency risk | NIS linked to the Israeli CPI
Assets
Cash and cash equivalents	0	0
Marketable securities		1,376
Trade receivables (including long-term trade receivables)	0	0
Accounts receivable	0	0
Inventories	0	0
Long-term restricted deposits	0	0
Long-term prepaid expenses	0	0
Property and equipment and intangible assets	0	0
Total assets	0	1,376
Liabilities
Trade payables	0	0
Employee benefits	0	0
Provisions	0	0
Other accounts payable (including accrued expenses)	0	0
Short-term bank loan	0	0
Financial derivatives	0	0
Other long-term accounts payable	0	43
Total liabilities	0	43
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	0	1,333
Currency risk | Euro
Assets
Cash and cash equivalents	426	160
Marketable securities		0
Trade receivables (including long-term trade receivables)	327	689
Accounts receivable	2	3
Inventories	0	0
Long-term restricted deposits	0	0
Long-term prepaid expenses	0	0
Property and equipment and intangible assets	0	0
Total assets	755	852
Liabilities
Trade payables	5	47
Employee benefits	0	0
Provisions	0	0
Other accounts payable (including accrued expenses)	50	70
Short-term bank loan	0	0
Financial derivatives	0	0
Other long-term accounts payable	0	0
Total liabilities	55	117
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	700	735
Currency risk | Other currencies
Assets
Cash and cash equivalents	72	22
Marketable securities		0
Trade receivables (including long-term trade receivables)	0	0
Accounts receivable	0	0
Inventories	0	0
Long-term restricted deposits	0	0
Long-term prepaid expenses	0	0
Property and equipment and intangible assets	0	0
Total assets	72	22
Liabilities
Trade payables	0	0
Employee benefits	0	0
Provisions	0	0
Other accounts payable (including accrued expenses)	0	0
Short-term bank loan	0	0
Financial derivatives	0	0
Other long-term accounts payable	0	0
Total liabilities	0	0
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	72	22
Non-monetary items
Assets
Cash and cash equivalents	0	0
Marketable securities		0
Trade receivables (including long-term trade receivables)	0	0
Accounts receivable	737	500
Inventories	2,235	2,260
Long-term restricted deposits	0	0
Long-term prepaid expenses	66	69
Property and equipment and intangible assets	1,511	1,299
Total assets	4,549	4,128
Liabilities
Trade payables	0	0
Employee benefits	381	533
Provisions	215	183
Other accounts payable (including accrued expenses)	321	339
Short-term bank loan	0	0
Financial derivatives	0	0
Other long-term accounts payable	0	0
Total liabilities	917	1,055
Total exposure in the statements of financial position in respect of financial assets and financial liabilities	$ 3,632	$ 3,073

FINANCIAL INSTRUMENTS (Detail_6

FINANCIAL INSTRUMENTS (Details 6) - Currency risk - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial instruments [line items]
Sensitivity analysis of equity increase (decrease), impact of 5% favourable change in NIS against Dollar	$ 12	$ (340)
Sensitivity analysis of equity increase (decrease), impact of 5% favourable change in EURO against Dollar	35	37
Sensitivity analysis of proft (loss) increase (decrease), impact of 5% favourable change in NIS against Dollar	12	(340)
Sensitivity analysis of proft (loss) increase (decrease), impact of 5% favourable change in EURO against Dollar	$ 35	$ 37

FINANCIAL INSTRUMENTS (Detail_7

FINANCIAL INSTRUMENTS (Details 7) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial instruments [line items]
Liabilities	$ 1,151	$ 12,190
Fair value
Disclosure of detailed information about financial instruments [line items]
Liabilities	490	11,713
Convertible notes
Disclosure of detailed information about financial instruments [line items]
Convertible notes	0	11,118	[1]
Convertible notes | Fair value
Disclosure of detailed information about financial instruments [line items]
Convertible notes	0	11,283	[2]
Liability in respect of royalties to the IIA and other government institutions
Disclosure of detailed information about financial instruments [line items]
Liability in respect of royalties to the IIA and other government institutions	1,151	1,072
Liability in respect of royalties to the IIA and other government institutions | Fair value
Disclosure of detailed information about financial instruments [line items]
Liability in respect of royalties to the IIA and other government institutions	$ 490	$ 430
[1]	Quoted market price on the TASE.
[2]	Including interest payable, but excluding the fair value of the embedded warrants.

FINANCIAL INSTRUMENTS (Detail_8

FINANCIAL INSTRUMENTS (Details 8) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial instruments - marketable securities		$ 3,173
Financial instruments - derivative instruments	$ 442	2,875
Level 1
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial instruments - marketable securities		3,173
Financial instruments - derivative instruments	0	0
Level 3
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial instruments - marketable securities		0
Financial instruments - derivative instruments	$ 442	$ 2,875

FINANCIAL INSTRUMENTS (Detail T

FINANCIAL INSTRUMENTS (Detail Textuals)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Customer Concentrations Risk | Credit risk | Sales revenue
Disclosure of detailed information about concentrations of risk that arises from contracts within scope of IFRS 17 [line items]
Concentration risk, percentage	44.00%	42.00%	42.00%

FINANCIAL INSTRUMENTS (Detail_9

FINANCIAL INSTRUMENTS (Detail Textuals 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [abstract]
Hypothetical percentage specified for increase or decrease in market price of company share price	10.00%
Gain (loss) from derivatives instruments, net	$ 2,433	$ 3,925	$ (216)

RELATED PARTIES (Details)

RELATED PARTIES (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)person	Dec. 31, 2017USD ($)person	Dec. 31, 2016USD ($)person
Disclosure of transactions between related parties [line items]
Number of persons employee compensation | person	8	9	9
Compensation to directors who are not employed	$ 284	$ 306	$ 278
Key executives personnel
Disclosure of transactions between related parties [line items]
Number of persons employee compensation | person	7	7	6
Number of persons for share based payment | person	7	7	6
Employee compensation	$ 1,835	$ 1,384	$ 1,590
Share-based payment	702	1,083	1,168
Total	2,537	2,467	2,758
Transaction amounts	2,821	2,773	$ 3,035
Carrying amount	$ 341	$ 1,147

RELATED PARTIES (Detail Textual

RELATED PARTIES (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of transactions between related parties [line items]
Revenue from contracts with customers	$ 10,670	$ 8,753	$ 7,764
Marketing agreement with Medtronic, Inc. ("Medtronic")
Disclosure of transactions between related parties [line items]
Revenue from contracts with customers	207	307	177
Fee and commission expense	$ 41	$ 61	$ 35

SUBSEQUENT EVENTS (Detail Textu

SUBSEQUENT EVENTS (Detail Textuals) ₪ / shares in Units, $ / shares in Units, $ in Thousands, ₪ in Millions	Jan. 28, 2019USD ($)$ / sharesshares	Jan. 28, 2019₪ / sharesshares	Jan. 16, 2019	May 27, 2018USD ($)	May 27, 2018ILS (₪)₪ / shares	Dec. 31, 2018USD ($)	Dec. 31, 2016USD ($)	Mar. 06, 2019shares	Feb. 03, 2019shares
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from issuing shares | $						$ 5,209	$ 998
Securities purchase agreement | 2018 Private Placement
Disclosure of non-adjusting events after reporting period [line items]
Share issued price per share | ₪ / shares					₪ 0.947
Proceeds from issuing shares				$ 6,000	₪ 20.8
Subsequent Events
Disclosure of non-adjusting events after reporting period [line items]
Threshold period for selling of ordinary shares for company?s directors and executive officers			(i) 180 days following the closing of the U.S. Tranche, (ii) the termination of the securities purchase agreement, or (iii) ten (10) months following the signing (November 15, 2019).
Subsequent Events | ADS
Disclosure of non-adjusting events after reporting period [line items]
Threshold period for additional fund raise after closing of initial public offering of its ADSs	180 days
Subsequent Events | U.S. investor | ADS | 2018 Private Placement
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued								1,170,707
Subsequent Events | Israeli investor | Ordinary shares | 2018 Private Placement
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued									10,994,185
Subsequent Events | Securities purchase agreement
Disclosure of non-adjusting events after reporting period [line items]
Percentage of common stock share outstanding	13.80%
Proceeds from issuing shares | $	$ 14,700
Subsequent Events | Securities purchase agreement | U.S. investor | ADS
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued	1,170,707	1,170,707
Share issued price per share | $ / shares	$ 9.55
Subsequent Events | Securities purchase agreement | Israeli investor | Ordinary shares
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued	10,944,185	10,944,185
Share issued price per share | (per share)	$ 0.32	₪ 1.1693
Subsequent Events | Securities purchase agreement | Investors | Ordinary shares
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued	46,115,395	46,115,395